Contents lists available at ScienceDirect

Heliyon



journal homepage: www.cell.com/heliyon

Research article

5[©]CelPress

Association between the pre-transplantation serum ferritin level and outcomes of hematopoietic stem cell transplantation: A systematic review and meta-analysis

Wenjue Pan¹, Qibei Teng¹, Huiqiao Chen, Liangning Hu, Xiaoyan Yue, Zijun Qian, Ruoyu Dong, Hongyu Zhou, Xiujie Zhao, Haowen Xiao^{**}, Shufen Wang^{*}

Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Rd., Hangzhou, 310016, Zhejiang province, PR China

ARTICLE INFO

Registry/Registry number: PROSPERO CRD42023448899 *Keywords:* Serum ferritin Hematopoietic stem cell transplantation Meta-analysis Fungal infection

ABSTRACT

Ba in	<i>ckground:</i> Iron overload, as indicated by evaluated serum ferritin (SF) level, occurs commonly patients with hematological diseases. To evaluate the association between pre-transplant SF
lev ter	rel and outcomes of hematopoietic stem cell transplantation (HSCT), we performed this sys- natic review and meta-analysis.
Me sea eli	<i>ethods</i> : PubMed, Embase, Web of Science and the Cochrane Library electronic database were arched from inception to August 2023, and 56 studies with 14149 patients were found to be gible.
Re	sults: An elevated pre-transplantation SF level was associated with inferior overall survival
(ha	azard ratio [HR],1.77; 95 % confidence interval [CI],1.61–1.96) and disease-free survival (HR,
1.8	36; 95 % CI, 1.58-2.19), and increased risk of non-relapse mortality (HR, 1.73; 95 % CI,
1.4	49–2.02), and relapse (HR, 1.46; 95 % CI, 1.29–1.65). However, no meaningful association was
ob	served between SF levels and acute graft-versus-host disease (GVHD) (risk ratio [RR], 1.09; 95
%	CI, 0.96–1.24), or chronic GVHD (RR, 0.95; 95 % CI, 0.79–1.16). Furthermore, an elevated pre-
ra	nsplantation SF level was associated with a higher risk of fungal infection (RR, 1.56; 95 % CI,
1.1	16-2.10), but not with bacterial infection (RR, 1.09; 95 % CI, 0.80-1.50). Moreover, an
ele	evated pre-transplantation SF level was related to a higher risk of death due to relapse/disease
pro	ogression (RR, 1.72; 95 % CI, 1.33–2.23) and infection (RR, 2.21; 95 % CI, 1.55–3.15), but not
de	ath due to GVHD (RR, 1.18; 95 % CI, 0.79–1.77).
Со	nclusions: A higher pre-transplantation SF level was significantly associated with a higher risk
of	relapse/disease progression and infections, which contributed to worse survival in patients
un	dergoing HSCT. In particular, a higher SF level was related to a higher risk of fungal infection,
inc reş	dicating that patients with a higher pre-transplantation SF level require more attention garding the risk of fungal infection after HSCT.

* Corresponding author.

** Corresponding author.

https://doi.org/10.1016/j.heliyon.2024.e37436

Received 28 February 2024; Received in revised form 4 August 2024; Accepted 3 September 2024

Available online 4 September 2024

E-mail addresses: haowenxiaoxiao@zju.edu.cn (H. Xiao), Shufen_wang@zju.edu.cn (S. Wang).

¹ Co-first author: Wenjue Pan and Qibei Teng have contributed equally to this article.

^{2405-8440/© 2024} The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Iron plays crucial roles in various physiological processes within organisms, including DNA synthesis, energy metabolism, oxygen transportation and storage, as well as electron transfer [1]. However, excess ferrous iron can cause an accumulation of reactive oxygen species (ROS) through the Fenton reaction, ultimately leading to cell damage, cell death, and organ failure [2]. Iron overload is characterized by the serum ferritin (SF) level exceeding the upper limit of the normal range (>150–300 ng/mL), in the absence of acute or chronic infectious/inflammatory conditions [3]. While methods, such as magnetic resonance imaging, liver biopsy, and super-conducting quantum interference device susceptometry are available for estimating iron overload [4,5], the SF level remains the most commonly used because of its easy accessibility.

Hematopoietic stem cell transplantation (HSCT) is widely acknowledged as one of the most effective therapeutic interventions for curing hematological diseases. Iron overload commonly occurs in patients with hematological diseases, likely stemming from frequent blood transfusions, reduced iron utilization due to impaired marrow function, and elevated transferrin saturation induced by high-dose chemo-/radiotherapy [6,7]. Some meta-analyses have indicated that an increased pre-transplantation SF level is associated with adverse outcomes following allogeneic HSCT (allo-HSCT) in patients with hematological malignancies (HM) [8–11]. Human leucocyte antigen (HLA)-identical sibling allo-HSCT is also considered a primary curative approach for patients diagnosed with hematological nonmalignant diseases (HNM), such as severe aplastic anemia (SAA) [12]. Patients requiring prolonged blood transfusion support are at a heightened risk of developing iron overload [13]; thus, the influence of the SF level on both HM and HNM should be examined separately. In addition, previous meta-analyses only included studies on allo-HSCT [8,9,14,15], warranting an examination of the correlation between the pre-transplantation SF level and the outcomes of autologous HSCT (auto-HSCT). Iron overload has been linked to an increased risk of hepatic sinusoidal obstruction syndrome (SOS) [16,17], infections [18], mucositis [19], and graft-versus-host disease (GVHD) [20], which can further negatively impact long-term survival after HSCT. However, a previously published meta-analysis failed to include numerous recent studies and did not thoroughly evaluate the association between the SF level and the risk of SOS after HSCT. Furthermore, the relationship of the pre-transplantation SF level to infections and GVHD remains controversial [11]. Therefore, a systematic review and meta-analysis was performed to gain a more thorough understanding of this field.

The primary objective of this review was to determine whether the evaluated pre-transplantation SF level was associated with: (1) overall survival (OS), (2) disease free survival (DFS), (3) non-relapse mortality (NRM), (4) relapse, (5) the risks of grades II-IV acute GVHD (aGVHD), (6) chronic GVHD (cGVHD), (7) SOS, or (8) infections. The secondary objectives were to analyze whether the associations were still significance in different subgroups defined by disease type (HM or HNM) and graft type (allogeneic, autologous HSCT, or umbilical cord blood transplantation).

2. Method

2.1. Registration and protocol

The systematic review protocol was registered on the "International Prospective Register of Systematic Review" with the registration number CRD42023448899. Additionally, this meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines [21].

2.2. Eligibility criteria and search strategy

Prospective or retrospective cohort studies, as well as case-cohort studies were incorporated to examine the correlation between the pre-transplantation SF level and clinical outcomes among patients undergoing HSCT. Searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Library database for articles published up to August 1, 2023 (Supplementary Table 1). The inclusion criteria were as follows: (1) assessed the association between SF levels and clinical outcomes in patients undergoing HSCT; (2) reported a hazard ratio (HR) or risk ratio (RR) and 95 % confidential interval (CI) for the associations or Kaplan-Meier plots from which the HR and 95 % CI could be estimated; (3) the number of patients was reported so that the RR could be calculated. Articles were excluded that met the following criteria: (1) non-English written studies, (2) reviews and meta-analyses, (3) case reports, (4) animal studies and *in vitro* studies, (5) book chapters, clinical guidelines, clinician perspectives, editorials, notes, comments, and letters without original studies, (6) SF level was measured post-transplantation, (7) no related outcomes of HSCT involving OS, DFS, NRM, relapse, aGVHD, cGVHD, infection, or SOS. A two-step selection process was employed to identify eligible studies. Three independent investigators (YXY, CHQ, and ZHY) conducted primary screening of all titles or abstracts. Subsequently, they assessed all potentially relevant articles through a comprehensive full-text reviews. Discrepancies were resolved through discussion and, when necessary, through consultation with a third investigator (WSF). This collaborative approach ensured consensus in the decision-making process.

2.3. Data extraction and quality assessment

Data extraction was independently conducted by three authors (WSF, PWJ, and TQP) using a standardized data collection form. The measures of associations were HRs, RRs, and 95 % CIs. Patients were categorized into higher and lower SF groups based on various cut-off values among the included articles. The outcomes of interest include OS, DFS, NRM, relapse, aGVHD, cGVHD, infection, SOS and causes of death (due to infection, progression or relapse, or GVHD). The characteristics recorded from the identified studies

include publication year, primary author, country, study design, cohort sample size, recruitment period, follow-up duration, age at enrollment, graft type, disease subtype, SF cut-off values, and outcome time point. In instances of discrepancies regarding study inclusion or data interpretation, a third investigator (XHW) was consulted to ensure consensus and accuracy.

2.4. Statistical analysis

Review Manager (RevMan) software version 5.4 (Cochrane, Copenhagen, Denmark) was used to analyze the data. A *p*-value of less than 0.05 was considered statistically significant for the effect of study-level variables. Multivariate-adjusted risk estimates were prioritized if they were reported in the original article; otherwise, unadjusted risk estimates were computed using the original data. In cases where HRs were not directly provided in the articles, Kaplan-Meier curves were analyzed using Engauge Digitizer version 12.1, and HRs along with their corresponding 95 % CIs were estimated using Richard Steven's Excel Workbook [22].

Cochran's Q-test and I^2 statistics were used to assess potential sources of heterogeneity in the included studies. Heterogeneity was considered statistically significant for the *p*-value <0.1 or I^2 > 50 %. In such cases, a random-effect model was used instead of fixed-effect model [23].

Potential publication bias was evaluated using multiple methods, including funnel plots, Egger's linear regression test, and Begg's rank correlation test, with the significance level set at p < 0.05 [24]. If a publication bias was indicated, the trim and fill method using STATA version 12.0 (StataCorp LP, College Station, TX, USA) was employed. This method allowed for the estimation of the number of missing studies and recalculates the pooled risk estimate by incorporating these missing studies [25].

3. Results

3.1. Study selection and study characteristics

Among the 6851 records identified in the databases, 4410 titles and abstracts were screened, and 87 manuscripts were assessed for eligibility. Among them, 56 articles [26–81] with 13836 patients, were included in the meta-analysis (Fig. 1). Most of the included studies were retrospective, and only three were prospective. The Trials were performed in Asia (n = 26), Europe (n = 16), North America (n = 12), South America (n = 1) and Oceania (n = 1). Among the included studies, 49 involved patients with allo-HSCT, with three including only patients with umbilical cord blood transplantation (UCBT), six involved patients with auto-HSCT, and one study included patients with either allo- or auto-HSCT. Thirty-four studies recruited patient with hematologic malignancies, three studies enrolled patients with non-hematologic malignancies (severe aplastic anemia), and 19 studies included both hematologic and



Fig. 1. Preferred reporting Items for systematic reviews and meta-analysis Flow Diagram.

Weight

4 0%

4.0% 1.9% 5.8%

9.7%

7.6%

4.0%

3.6%

0.8% 2.5% 7.4%

6.7% 3.0% 7.9% 6.3%

6.0% 80.0%

4.3% 4.5%

6.3%

4.9%

100.0%

5 10

non-hematologic malignancies. The SF cut-off level in the included studies varied greatly, ranging from 250 to 4000 ng/mL. Twenty-six studies employed an SF level threshold of 1000 ng/mL, five used 1500 ng/mL, four used 2500 ng/mL, three used 500 ng/mL, two studies used 2000 ng/mL, and others used independent thresholds. The characteristics of the included studies were summarized in Supplementary Table 2. We assessed study quality using the Newcastle-Ottawa quality assessment scale [82], with an average score of 7.4. Moreover, 54 of the studies achieved a score of six or higher (Supplementary Table 3).

3.2. The impact of pre-transplantation SF level on outcomes

3.2.1. Overall survival (OS)

Data to calculate the impact of the pre-transplantation SF level on OS among patients were available from 47 studies [26–41,43, 45–49,51,53–56,58,60,61,63,65–72,74–76,78–80]. A random-effects model was used to calculate the pooled HR with 95 % CI due to moderate heterogeneity ($I^2 = 42$ %; p = 0.001). The results showed that OS was significantly poorer in the higher SF group (HR, 1.77; 95 % CI, 1.61–1.96; Fig. 2A). To investigate the origins of the heterogeneity, subgroup analyses were performed based on several parameters, including study location, cut-off value, variable type, disease type, graft type (allogeneic, or autologous HSCT) and outcome time point; However, no factor was identified that significantly altered the HR (Supplementary Table 4).

3.2.2. Disease free survival (DFS)

The relationship between higher pre-transplantation SF level and DFS was reported in 20 studies [26,27,29,34,36,37,39,40,45,46, 49,54,61,64,68–70,72,75,78]. Considering the substantial heterogeneity ($I^2 = 52$ %; p = 0.004), the HR and 95 % CI were calculated

B. Disease free survival

A.Overall survival

Study or Subgroup Study or Subgroup Hazard Ratio Favours Favours [higher SF] [lower SF] Hazard Ratio Favours Favours (higher SFI (Lower SFI Weight allo-HSCT allo-HSCT 1.10 [0.57, 2.12] Aki 2012 Aki 2012 .35 [0.81, 2.25] 2.30 [0.77, 6.87] 1.98 [1.23, 3.19] 1.20 [0.98, 1.47] 2.49 [1.76, 3.52] Boehm 2014 4.5% Alessandrino 2010 1.40 [1.08, 1.81] Cho 2019 Armand 2008 1.50 [1.01.2.23] 3.2% Cremers 2019 0.6% 4.2% 3.1% 6.40 [1.97, 20.79] 1.15 [0.86, 1.54] Arndt 2014 Dadwal 2015 Artz 2016 Efebera 2009 2.00 [0.83, 4.82 Barba 2013 1.80 [1.20, 2.70] Jacobi 2016 2.06 [1.06, 4.01] 1.99 [0.97, 4.08] Boehm 2014 1.70 [0.33, 8,76] 0.3% Jang 2014 6.0% 2.5% 0.7% 5.4% Chee 2017 Cho 2019 1.66 [1.47, 1.87] 1.90 [1.17, 3.09] -Kim 2008 1.35 [0.23, 7.92 Lin 2022 0.95 [0.38, 2.37] Cremers 2016 1.86 [0.60, 5.77] 1.60 [1.12, 2.29] 2.40 [1.60, 3.60] 2.96 [1.32, 6.64] 1.83 [1.32, 2.54] Oran 2014 Penack 2019 Cremers 2019 1.20 [1.00, 1.44] 2.6% 0.7% 4.7% Dadwal 2015 Efebera 2009 2.15 [1.34, 3.45] 2.33 [0.77, 7.05] Sivgin 2012 Tachibana 2012 1.12 [0.88, 1.44] Fingrut 2021 Hilken 2017 1.83 [1.32, 2.34] 1.27 [0.82, 1.97] 2.08 [1.31, 3.30] 1.76 [1.48, 2.08] Tanaka 2015 1.4% 1.6% 1.3% 1.4% 3.2% 1 55 10 75 3 201 Vahlin 2011 ubtotal (95% CI) 1.55 [0.75, 3.20] 2.09 [1.06, 4.12] 1.88 [0.88, 4.02] 2.47 [1.19, 5.13] Jacobi 2016 Jang 2014 Heterogeneity:Chi2 = 27.64, df = 15 (P = 0.02); |2 = 46% Kanda 2011 Kataoka 2009 2.44 [1.64, 3.63] auto-HSCT 0.6% 1.4% 0.7% 3.2% Kim 2008 Lim 2010 2.45 [0.76, 7.90] 2.00 [0.97, 4.12] Alva 2018 .96 [1.05, 3.66] Sivgin 2016 4.76 [2.59, 8.75] Lin 2022 1.39 [0.45, 4.29] Strasser-Weippl 2014 Subtotal (95% CI) 1.85 [1.19, 2.88] 2.54 [1.42, 4.54] Mahindra 2009 1.82 [1.23, 2.69] 1.62 [1.23, 2.69] 1.68 [0.94, 3.00] 2.00 [1.32, 3.03] 3.70 [1.28, 10.70] 2.0% 3.0% 0.8% 2.4% Ohmoto 2017 Oran 2014 neity:Chi2 = 6.60, df = 2 (P = 0.04); Pan 2023 Umbilical cord blood tr nlantatio Penack 2019 2.50 [1.50, 4.17] Al Malki 2020 Subtotal (95% CI) 1.82 [1.04, 3.18] 1.82 [1.04, 3.18] 1.73 [1.09, 2.75] 2.28 [1.29, 4.03] 2.16 [1.34, 3.48] Prem 2019 Pullarkat 2008 2.7% 2.0% 2.6% 1.2% 2.3% 2.0% 1.2% 2.6% Sakamoto 2013 Sivgin 2012 Sucak 2010(allo) 2.46 [1.10, 5.50] Total (95% CI) 1.86 [1.58, 2.19] 2.46 [1.10, 5.50] 1.44 [0.86, 2.41] 1.87 [1.05, 3.33] 1.03 [0.45, 2.36] Heterogeneity: Chi² = 39.31, df = 19 (P = 0.004); l² = 52% Tachibana 2012 Takasaki 2012 0.1 0.2 0.5 Tanaka 2015 1.79 [1.11, 2.89] 0.4% 2.7% 1.5% 1.97 [0.46, 8.44] 1.79 [1.13, 2.84] Thambiah 2016 Wahlin 2011 e 2012 Verm 1.35 [0.66, 2.76] Yoon 2020 7.22 [1.90, 27.44 0.5% Subtotal (95% CI) 1.69 [1.54, 1.87] 8.13 (P = 0.02); I leterogeneity: C auto-HSCT 1.6% 2.35 [1.21, 4.56] 2.02 [1.29, 3.16] 4.69 [2.39, 9.20] 1.72 [1.03, 2.87] 2.8% Mahindra 2008 Sivgin 2016 1.6% 1.0% 2.4% 1.4% 9.8% Strasser-Weippl 2014 Sucak 2010(auto) 3.58 [1.72, 7.45] 2.52 [1.77, 3.59] Subtotal (95% CI) terogeneity: Chi 13 (P = 0.13); |2 = 44% Umbilical cord blood transplantation 2.0% 1.4% 1.1% 4.6% Al Malki 2020 2.26 [1.28, 3.99] Konuma 2014 0.77 [0.37, 1.60] to 2014 2.00 [0.87, 4.60] 1.54 [0.78, 3.02] Subtotal (95% CI) eity: Chi 52. df = 2 (P = 0.06): 100.0% Total (95% CI) 1.77 [1.61, 1.96] Heterogeneity: Chi² = 80.01, df = 46 (P = 0 001); l² = 43% 0.01 10 01 100

Fig. 2. Forest plots illustrating study specific and pooled hazard ratio (HR) and 95 % confidence interval (CI) for the effect of a higher serum ferritin (SF) level vs a lower SF level. **A:** Overall Survival, grouped by graft type (allogeneic, autologous, or umbilical cord blood transplantation); **B:** Disease-Free Survival, grouped by graft type (allogeneic, autologous, or umbilical cord blood transplantation).

4

using a random-effects model. The pooled estimate showed a significant association between higher SF level and inferior DFS (HR, 1.86; 95 % CI, 1.58–2.19; Fig. 2B). Additionally, subgroup analyses explored the potential sources of heterogeneity, examining various factors such as: study location, cut-off value, variable type, disease type, graft type, and outcome time point, and no factor was identified that significantly altered the HR (Supplementary Table 5).

3.2.3. Non-relapse mortality (NRM)

Pooled results from 19 studies [27,28,33,35–37,40,41,48,55,56,64,65,72,75,77–80] showed that the NRM was significantly higher in patients with a higher SF level (HR, 1.73; 95 % CI, 1.49–2.02; Fig. 3A) than in those with a lower SF level. Heterogeneity among the studies included in the analysis was moderate ($I^2 = 35$ %; p = 0.06). Subgroup analyses revealed that the association between the SF level and NRM remained significant according to study location, cut-off value, variable type, disease type, graft type, and outcome time point (Supplementary Table 6).

3.2.4. Relapse

Sixteen studies [27,33,35–37,41,46,48,53,55,60,64,67,75,78] analyzed the relationship between the SF level and relapse. The risk of relapse was significantly higher in patients with a higher SF level (HR, 1.46; 95 % CI, 1.29–1.65; Fig. 3B) without obvious heterogeneity ($I^2 = 22$ %; p = 0.20). The association between higher pre-transplantation SF level and the risk of relapse did not change in the subgroup analysis (Supplementary Table 7).

3.2.5. Grades II-IV aGVHD

Data from twenty-one studies [27,36,39,41,42,48,49,51–54,56,63,66–68,72,75,79–81], involving 3111 patients who underwent allo-HSCT, of whom 1318 developed grades II-IV aGVHD, were used to assess the influence of an elevated SF levels on the cumulative occurrence of grades II-IV aGVHD. Pooled analysis of the risk of grades II-IV aGVHD suggested no significant difference between a higher SF level versus lower SF level (RR, 1.09; 95 % CI, 0.96–1.24; Fig. 4A), with moderate heterogeneity ($I^2 = 52$ %; p = 0.004). The pooled RR did not reach significance in the subgroup analysis by study location, cut-off value, variable type, disease type, or graft type (Supplementary Table 8).

3.2.6. Chronic GVHD (cGVHD)

The cumulative incidence of cGVHD was investigated in 18 studies [27,36,40–42,48,49,51–54,56,63,67,68,72,75,81], with a total of 2307 participants and 833 developed cGVHD. The pooled RR showed that a higher SF level had no significant association with the incidence of cGVHD (RR, 0.93; 95 % CI, 0.78–1.12; Fig. 4B), with substantial heterogeneity ($l^2 = 55$ %; p = 0.003). The subgroup analysis revealed that patients with SAA with a higher pre-HSCT SF level tended to have a higher incidence of cGVHD (RR, 1.64; 95 % CI, 1.04–2.59; Fig. 4B). The pooled RR in other subgroups did not show significant changes (Supplementary Table 9).

3.2.7. Sinusoidal obstruction syndrome (SOS)

Data to calculate the impact of a higher SF level on the cumulative incidence of SOS among patients were available from eight studies [44,49,50,52,56,57,59,71], with a total of 1318 HSCT patients, of whom 388 patients developed SOS. The pooled RR suggested that patients with a higher SF level have a higher risk of SOS (RR, 2.11; 95 % CI, 1.12–3.98; Fig. 4C) with significant heterogeneity ($l^2 = 88 \%$; p < 0.0001). The association between higher pre-transplantation SF level and the risk of SOS did not differ substantially in the subgroup analysis, except that elevated pre-transplantation SF level tended to be associated with an increased incidence of SOS in patients with hematologic malignancies (HR, 1.87; 95 % CI, 0.60–2.85; Supplementary Table 10).

3.2.8. Infections

For extensive infections, data on 643 patients from six articles [27,45,49,52,60,68] were available. The pooled estimate showed a significant association between higher SF level and higher incidence of extensive infection (RR, 1.62; 95 % CI, 1.12–2.36; Fig. 5A) with substantial heterogeneity ($I^2 = 70$ %; p = 0.005). For fungal infection, the SF level was examined in six studies [39,62,71,75,79,81] with 1244 participants and 166 fungal infections. The association between higher SF level and higher risk of fungal infection was significant (RR, 1.56; 95 % CI, 1.16–2.10; Fig. 5B) without heterogeneity ($I^2 = 0$ %; p = 0.78). However, for bacterial infections, the pooled results from four studies [47,75,79,81] with 470 participants and 208 bacterial infections showed no significant association between the higher SF group (RR, 1.09; 95 % CI, 0.80–1.50; Fig. 5C) and the lower SF group, with substantial heterogeneity ($I^2 = 53$ %; p = 0.09).

3.2.9. Cause of death

To examine the correlation between the pre-transplantation SF level and various post-HSCT mortality factors, three primary causes: relapse or disease progression, infections, and GVHD were examined. The pooled results from four studies [35,40,56,64] (1181 participants and 216 deaths due to relapse or disease progression) showed that death due to relapse or disease progression was significantly higher in the higher SF group (RR, 1.72; 95 % CI, 1.33–2.23; Fig. 6A) than in the lower SF group, without heterogeneity ($I^2 = 0$ %; p = 0.55). Pooled results from seven studies [35,40,48,56,63,64,75] (1700 participants and 129 deaths due to infection) indicated that death due to infection was also significantly increased in the higher SF group (RR, 2.21; 95 % CI, 1.55–3.15; Fig. 6B) compared to the lower SF group without heterogeneity ($I^2 = 0$ %; p = 0.65). the pooled results from seven studies [35,40,48,52,56,63, 75] (1462 participants and 92 deaths due to GVHD) suggested that the risk of death due to GVHD was not significantly different between the two groups (RR, 1.18; 95 % CI, 0.79–1.77; Fig. 6C) without heterogeneity ($I^2 = 0$ %; p = 0.92).

A. Non-relapse mortality

Study or Subgroup	Hazard Ratio	Favours Favours	Weight
allo-HSCT		[lower SF] [higher SF]	
Alessandrino 2010	1.42 [1.03, 1.96]		9.5%
Barba 2013	1.80 [1.10, 2.95]	_	6.1%
Chee 2017	2.82 [1.33, 5.98]	_	3.3%
Cho 2019	1.54 [0.76, 3.12]		3.7%
Cremers 2019	1.10 [0.80, 1.51]		9.6%
Efebera 2009	2.00 [0.52, 7.69]		1.2%
Fingrut 2021	1.00 [0.50, 1.99]		3.8%
Kataoka 2009	2.55 [1.40, 4.64]		4.7%
Mahindra 2009	1.75 [1.20, 2.55]	_	8.2%
Penack 2019	3.10 [1.50, 6.41]		3.5%
Prem 2019	1.80 [1.15, 2.82]	_	6.8%
Tachibana 2012	1.83 [1.16, 2.89]	_	6.7%
Tanaka 2015	1.60 [0.83, 3.08]		4.1%
Vaughn 2015	1.98 [1.37, 2.86]		8.4%
Wahlin 2011	1.63 [0.88, 3.02]		4.5%
Wermke 2012	1.20 [0.52, 2.77]		2.8%
Yoon 2020	12.90 [3.40, 48.94]		1.2%
Subtotal (95% CI)	1.74 [1.46, 2.07]	•	88.2%
Heterogeneity:Chi ² = 2	27.27, df = 16 (P = 0.04);	l² = 41%	
auto-HSCT			
Mahindra 2008	1.60 [1.08, 2.37]		7.9%
Subtotal (95% CI)	1.60 [1.08, 2.37]	~	7.9%
Umbilical cord bloo	d transplantation		
Al Malki 2020	2.18 [1.10, 4.32]		3.9%
Subtotal (95% CI)	2.18 [1.10, 4.32]		3.9%
Total (95% CI)	1.73 [1.49, 2.02]	•	100.0%
Heterogeneity:Chi ² = 3	P = 0.06	l ² = 35%	100.0%
, lotor ogeneity. of it			
	0.02	0.1 1 10 50	5

B. Relapse

Study or Subgroup	Hazard Ratio	Favours Favours	Weight
allo-HSCT		[lower SF] [nigher SF]	-
Barba 2013	1.10 [0.70, 1.73]		7.4%
Chee 2017	1.37 [1.01, 1.86]		16.3%
Cho 2019	2.89 [0.95, 8.79]		1.2%
Cremers 2019	1.30 [1.01, 1.67]		23.8%
Fingrut 2021	1.49 [0.66, 3.36]		2.3%
Jang 2014	3.58 [1.36, 9.43]	· · · ·	1.6%
Kataoka 2009	1.55 [0.96, 2.50]	•	6.6%
Lim 2010	1.30 [0.59, 2.86]		2.4%
Ohmoto 2017	1.75 [1.04, 2.94]		5.6%
Penack 2019	2.20 [1.20, 4.03]	· · · · · ·	4.1%
Sakamoto 2013	1.81 [1.11, 2.95]		6.3%
Tanaka 2015	1.10 [0.64, 1.89]		5.2%
Wahlin 2011	2.07 [1.15, 3.73]		4.4%
Subtotal (95% CI)	1.47 [1.29, 1.68]	\diamond	87.2%
Heterogeneity: Chi ² =	12.74, df = 12 (P = 0.39); l ² = 6	%	
auto-HSCT			
Mahindra 2008	1.76 [1.18, 2.63]		9.5%
Subtotal (95% CI)	1.76 [1.18, 2.63]	\diamond	9.5%
Heterogeneity: Not ap	plicable		
Umbilical cord blood	transplantation		
Al Malki 2020	0.50 [0.16, 1.56]		1.2%
Konuma 2014	0.76 [0.33, 1.75]		2.2%
Subtotal (95% CI)	0.66 [0.34, 1.29]		3.3%
Heterogeneity: Chi ² = 0	0.34, df = 1 (P = 0.56); l ² = 0%		0.070
	4 46 14 20 4 651		400.007
Total (95% CI)	1.40 [1.29, 1.65]		100.0%
Heterogeneity: Chi ² =	19.34, df = 15 (P = 0.20); l ² = 2	2%	
		0.1 0.2 0.5 1 2 5	10

(caption on next page)

Fig. 3. Forest plots illustrating study specific and pooled hazard ratio (HR) and 95 % confidence interval (CI) for the effect of a higher serum ferritin (SF) level vs a lower SF level. **A:** Non-Relapse Mortality, grouped by graft type (allogeneic, autologous, or umbilical cord blood transplantation); **B:** Relapse, grouped by graft type (allogeneic, autologous, or umbilical cord blood transplantation).

A. Grades II-IV acute GVHD

Study or Subgroup ematologic malignar	Events Tota	I Events	s Total	Risk Ratio	Favours Favours	Weight
ematologic malignar					llower SEL [bigher SE]	
	ncies				Found of 1 Fulginer of 1	
Cho 2019	31 104	23	94	1 22 [0 77 1 93]		4.7%
Kim 2008	6 16	7	22	1 18 [0 49 2 84]	<u> </u>	1.8%
Konuma 2014	31 49	50	84	0.00 [0.40, 2.04]	-	8.1%
Kuineein 2020	45 20	40	20	0.04 (0.57, 1.10)		4.4%
Kupesiz 2020	10 50	10	40	4.05 (0.57, 1.53)		2.4%
Lim 2010	13 55	9	40	1.25 [0.59, 2.00]		6.6%
Manindra 2009	28 /5	76	147	0.72 [0.52, 1.01]		7.5%
Tachibana 2012	49 122	58	127	0.88 [0.66, 1.17]		6.0%
Tanaka 2015	28 79	45	111	0.87 [0.60, 1.27]		2 9%
Wermke 2012	12 33	13	55	1.54 [0.80, 2.96]		1 59/
Yoon 2020	5 9	5	26	2.89 [1.08, 7.70]		45 9%
Subtotal (95% CI)	570		742	0.97 [0.82, 1.14]	Y	40.070
Total events	218	311				
Heterogeneity: Chi ² = 12	2.15, df = 9 (P =	0.20); l ² =	26%			
evere aplastic anem	ia					
Lin 2022	44 97	10	50	2 27 [1 25 4 12]		3.4%
Dan 2022	1 17	6	48	0.47 [0.06 3.63]		0.4%
7hone 2017	44 97	20	60	1 10 10 76 1 971		4 8%
Citary 2017 Published (0E9/ CI)	14 27	30	467	1.19 [0.70, 1.07]	A 1	8.6%
Subtotal (95% CI)	141		107	1.45 [0.76, 2.00]		0.070
Total events	59	46				
Heterogeneity: Chi ² = 4.	17, df = 2 (P = 0	.12); l ² = 5	52%			
ath						
Al Malki 2020	11 00	44	72	0.95 (0.52 1.27		4.6%
Ar walki 2020	11 23	41	73	1 25 [1 10 1 64]		9 2%
Dadwal 2015	114 220	99	257	1.35 [1.10, 1.64]	1	0.6%
⊢ingrut 2021	82 114	43	55	0.92 [0.77, 1.10]		7.0%
Kataoka 2009	56 132	49	132	1.14 [0.85, 1.54]		7.3%
Pullarkat 2008	53 84	45	106	1.49 [1.13, 1.96]		1.1%
Sakamoto 2013	23 71	50	140	0.91 [0.61, 1.36]		5.5%
Sivgin 2012	13 51	5	33	1.68 [0.66, 4.28]		1.7%
Subtotal (95% CI)	695		796	1.13 [0.94, 1.36]	۰	45.5%
Total events	352	332				
Heterogeneity: Chi ² = 15	5.50. df = 6 (P =	0.02); l ² =	61%			
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
Total (95% CI)	1406		1705	1.09 [0.96, 1.24]		100.0%
Total events	629	689			•	
Heterogeneity Chi2 - 20	9.23. df = 19 (P =	= 0.004); F	2 = 52%			
neterogeneity. Chir - 38			02.70			
Heterogeneity. Chir – 38			- 02.10	0.01	0.1 1 10	100
Chronic GV	HD	_		0.01	0.1 1 10	100
Chronic GV	HD higher S Events T	F Lo	wer SF	0.01	0.1 1 10	100 Weigt
Chronic GV	HD higher S Events T	F Lo otal Eve	wer SF	0.01	L I I IO Favours Favours [lower SF] [higher SF]	100 Weigh
Chronic GV Study or Subgroup lematologic maligna	HD higher S Events T ancies	F Lo otal Eve	wer SF	0.01	L I 1 10	100 Weigh 8.4%
Chronic GV Study or Subgroup fematologic maligna Cho 2019	HD higher S Events T ancies 40 10	F Lo otal Eve	wer SF ents Tota 9 94	0.01 I Risk Ratio 0.93 (0.66, 1.30	Favours Favours [ower SF]	Weigh 8.4%
Chronic GV Study or Subgroup fematologic maligna Cho 2019 Efebera 2009	HD higher S Events T ancies 40 10 15 4	F Lo otal Eve 4 3 7 1	wer SF ents Tota 9 94 2 16	0.01 Risk Ratio 0.93 [0.66, 1.30 0.43 [0.26, 0.70	O.1 1 10 Favours Favours [lower SF] [higher SF] []]	Weigh 8.4% 6.2%
Chronic GV Study or Subgroup tematologic maligna Cho 2019 Efebera 2009 Kim 2008	HD higher S Events T ancies 40 10 15 4 4	F Lo otal Eve 4 3 7 1 8	wer SF ents Tota 9 94 2 16 9 16	0.01 Risk Ratio 0.93 [0.66, 1.30 0.43 [0.26, 0.70 0.88 [0.39, 2.01	0.1 1 10	Weigt 8.4% 6.2% 3.5%
Chronic GV Study or Subgroup fematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014	HD higher S Events T ancies 40 10 15 4 4 14 4	F Lo otal Eve 4 3 7 1 8 9 1	wer SF ents Tota 9 94 2 16 9 16 7 84	0.01 Risk Ratio 0.93 [0.66, 1.3C 0.43 [0.26, 0.7C 0.88 [0.39, 2.0] 1.44 [0.76, 2.61		8.4% 6.2% 3.5% 5.0%
Chronic GV Study or Subgroup fematologic maligne Cho 2019 Efebera 2009 Konuma 2014 Kubasiz 2020	HD higher S Events T ancies 40 10 15 4 4 15 4 4 14 4 15 3	F La otal Eve 4 3 7 1 8 9 1 0 1	wer SF ents Tota 9 94 2 16 9 16 7 84 5 30	0.01 Risk Ratio 0.93 (0.66, 1.3 0.43 (0.26, 0.70 0.48 (0.39, 2.01 1.44 (0.76, 2.61 1.00 (0.60, 1.66	Favours Favours [lowerSF] higherSF]	100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2%
Chronic GV Study or Subgroup tematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kupesiz 2020 Lim 2010	HD higher S Events T ancies 40 10 15 4 4 14 4 15 3 13 5	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1	wer SF 9 94 2 16 9 16 7 84 5 30 0 46	0.01 Risk Ratio 0.93 [0.66, 1.30 0.43 [0.26, 0.77 0.89 [0.39, 2.01 1.41 [0.76, 2.81 1.00 [0.60, 1.66 1.13 [0.65, 2.33		Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1%
Chronic GV Study or Subgroup fematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kulpesiz 2020 Lim 2010 Mabindra 2009	HD higher S Events T ancies 40 10 15 4 4 14 4 15 3 13 5 20 7	F Lo otal Eve 4 3 7 1 8 1 9 1 0 1 3 1 5 3	wer SF ents Tota 9 94 2 16 9 16 7 84 5 30 0 46 8 147	0.01 Risk Ratio 0.93 (0.66, 1.3 0.43 (0.26, 0.7 0.48 (0.39, 2.01 1.41 (0.76, 2.41 1.00 (0.60, 1.66 1.00 (0.60, 1.66 1.00 (0.60, 1.66 1.00 (0.72, 0.68) 0.72 (0.72, 0.68) 0.72 (0.72, 0.68) 0.72 (0.72, 0.68) 0.72 (0.72, 0.68) 0.72 (0.72, 0.68) 0.72 (0.72, 0.72) 0.72 (0.72) 0.72	Eavours Fevours [ower SF] Picher SF]	Weigh 8.4% 6.2% 3.5% 6.2% 4.1% 4.8%
Study or Subgroup Hematologic maligna Cho 2019 Elebera 2009 Kim 2008 Konuma 2014 Kuipesiz 2020 Lim 2010 Mahindra 2009 Mahindra 2012	HD higher S Events T ancles 40 10 15 4 4 14 4 14 4 13 5 13 5 10 7 40 7	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7	wer SF ents Tota 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 100	0.01 0.03 [0.66, 1.30 0.43 [0.26, 0.77 0.88 [0.39, 2.07 1.44 [0.76, 2.81 1.00 [0.60, 1.66 1.13 [0.55, 2.33 0.52 [0.27, 0.98 0.82 1.02	Eavours Favours Iownr SFI prigner SFI	4.1% Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.8% 9.3%
Chronic GV Study or Subgroup fematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kuipesiz 2020 Lim 2010 Mahindra 2009 Tachibana 2019	HD higher S Events T ancles 40 10 15 4 4 14 4 15 3 13 5 10 7 40 8	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6	wer SF ents Tota 9 94 2 16 9 16 7 84 45 30 0 46 8 147 1 109	0.01 Risk Ratio 0.93 [0.66, 1.30 0.43 [0.26, 0.77 0.89 [0.39, 2.01 1.41 [0.76, 2.45 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.67 0.82 [0.27, 0.98 0.82 [0.82, 1.02, 7, 0.88 0.82 [0.82, 1.02, 7, 0.88] 0.82 [Eavours Favours Favours Favours [owerSF] PrigherSF]	Weigh 8.4% 6.2% 3.5% 6.2% 4.1% 4.8% 9.3% 8.7%
Study or Subgroup lematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kuipesiz 2020 Lim 2010 Mahindra 2009 Tachibana 2012 Tachibana 2012	HD higher S Events T ancies 40 10 15 4 4 4 15 3 13 5 10 7 40 8 43 7	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 1 5 3 7 6 9 9 4	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 err	0.01 0.03 [0.66, 1.30 0.43 [0.26, 0.77 0.89 [0.39, 2.07 1.47 [0.76, 2.61 1.13 [0.55, 2.33 0.52 [0.27, 0.89 0.82 [0.62, 1.09 0.82 [0.62, 1.09 0.82 [0.62, 1.09 0.82 [0.62, 1.09 0.82 [0.62, 1.09] 0.85 [- Favours Favours [ower GP] Popular SF]	4,100 Weigh 8,4% 6,2% 3,5% 5,0% 6,2% 4,1% 4,8% 9,3% 8,7% 56,2%
Chronic GV Study or Subgroup Iematologic maligne Cho 2019 Elebena 2009 Konuma 2014 Konuma 2014 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (9% C)	HD higher S Events T ancies 40 10 15 4 4 14 4 15 3 13 5 10 7 40 8 7 53	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653	0.01 0.01 0.33 (0.66, 1.33 0.43 (0.26, 0.73 0.89 (0.39, 2.01 1.00 (0.60, 1.66 1.13 (0.55, 2.33 0.52 (0.27, 0.39 0.82 (0.26, 1.13 0.82 (0.26, 1.13 0.82 (0.26, 1.13 0.52 (0.56, 1.13) 0.52 (0.56,		4.8% 4.2% 3.5% 6.2% 4.1% 4.8% 9.3% 5.6% 5.6% 5.6% 5.6%
Chronic GV Study or Subgroup Iematologic maligne Cho 2019 Efebera 2009 Konuma 2014 Kujesic 2020 Lim 2010 Mahindra 2009 Tachibena 2012 Tanaka 2014 Subtotal (95% Ci) Total events	HD higher S Events T ancies 40 10 15 4 4 14 4 14 4 13 5 13 5 10 7 53 194	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 2	wer SF mts Tota 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1	 Risk Ratio 0.93 [0.66, 1.3; 0.43 [0.28, 0.7] 0.89 [0.39, 2.0] 1.47 [0.76, 2.6] 1.00 [0.60, 1.66 1.10 [0.52, 2.3] 0.22 [0.27, 0.38 0.28 [0.28, 0.38 0.28 [0.28,	Eavours Favours [ower 9F] Projector SF]	4 100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.1% 4.1% 9.3% 8.7% 56.2%
Study or Study of Stu	HD higher S Events T ancles 40 10 15 4 4 4 15 3 13 5 10 7 40 8 43 7 53 194 24.23, df = 8 (P	F Lo otal Eve 4 3 7 1 8 9 1 0 1 5 3 7 6 9 4 2 2 2 4 = 0.002);	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 1 ² = 67%	0.01 0.03 [0.66, 13: 0.43 [0.26, 0.76 0.48 [0.39, 2.07 1.47 [0.76, 2.61 1.09 [0.65, 2.33 0.52 [0.27, 0.39 0.82 [0.62, 1.06 1.51 [1.10, 2.06 0.90 [0.69, 1.19		4.100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.8% 9.3% 8.7% 56.2%
Chronic GV Study or Subgroup tematologic maligna Cho 2019 Efebera 2009 Konuma 2014 Konuma 2014 Konuma 2014 Konuma 2014 Mahindra 2009 Tachibana 2012 Subtolai (95% Ci) Total events Heterogeneity: Ch ² Postero and Charles Subtolai (95% Ci) Total events	HD higher S Events T ancies 40 10 15 4 4 15 3 13 5 10 7 40 6 4 3 7 5 5 10 7 40 2 43 7 5 5 10 7 40 2 43 7 5 5 10 7 40 7 8 40 7 10 7 10 7 10 7 10 7 10 7 10 7 10 7 1	F Lo otal Event 4 3 7 1 8 9 1 3 1 5 3 7 6 9 4 2 24 = 0.002);	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 ² = 67%	 Risk Ratio 0.93 (0.66, 1.30 0.43 (0.26, 0.77 0.89 (0.39, 2.01 1.44 (0.76, 2.61 1.00 (0.60, 1.66 1.13 (0.52, 2.33 0.52 (0.27, 0.58 0.82 (0.62, 1.06 0.51 (1.10, 2.06 0.50 (0.68, 1.19 	Eavours Favours [ower SF] Digher SF]	4100 Weigt 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.1% 4.8% 9.3% 8.7% 56.2%
Study or Study of Study or Study of Study or Study of Study or Study of Stu	HD higher S Events T ancles 40 10 15 4 4 4 4 4 4 5 5 10 7 40 8 43 7 5 5 104 24.23, df = 8 (P mia	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 2 4 = 0.002);	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 ² = 67% 6 46	0.01 0.03 [0.66, 13: 0.43 [0.26, 0.77 0.48 [0.38, 2.07 1.41 [0.76, 2.61 1.03 [0.56, 2.33 0.52 [0.27, 0.68 0.82 [0.62, 106 1.51 [1.10, 2.06 0.90 [0.68, 1.19 2.38 [1.07 = 22	O.1 1 10 Favours Favours [over SF] higher SF]	100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 9.3% 8.7% 56.2% 3.5%
Chronic GV Study or Subgroup tematologic mailgnz Cho 2019 Erebena 2009 Konuma 2014 Konuma 2014 Konuma 2014 Lim 2010 Mahindra 2019 Tanika 2015 Subtolai (95% CI) Todal events Heterogeneity: Chi ² = Severe aplastic am	HD higher S Events T 40 10 15 4 14 4 15 5 13 55 10 7 40 8 43 7 53 194 24.23, df = 6(P mia 28 5 28	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 2 4 = 0.002); 1	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 I ² = 67% 6 46 6 16	0.01 0.01 0.33 (0.66, 1.33 0.43 (0.26, 0.77 0.88 (0.39, 2.01 1.40 [0.66, 1.66 1.00 [0.60, 1.66 1.00 [0.60, 1.66 1.10 [0.65, 2.26 0.90 [0.65, 1.22 0.90 [0.65, 5.25 0.90 [0.65, 5.25]	Favours Favours [owerSF] PicherSF]	Weigh 8.4% 6.2% 3.5% 6.2% 4.1% 4.1% 8.7% 56.2% 3.5% 1.3%
Chronic GV Study or Subgroup Hematologic maligni Cho 2019 Efshera 2009 Kim 2009 Kim 2009 Kim 2009 Kim 2001 Mahindra 2001 Tanihera 2012 Tanika 2015 Subtotal (5% Ct) Total events Heterogeneity: ChP = Severe aplastic aner Lin 2022 Pan 2023 -	HD higher S Events T ancies 40 10 15 4 41 4 15 3 13 5 10 7 40 8 43 7 10 7 40 8 43 7 10 7 40 4 43 7 104 24 23, df = 8(10) 28 5 2 1 104 28 5 2 1 104 28 5 2 1 105 105 105 105 105 105 105 10	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 24 = 0.002); 1	wer SF ents Tota 9 94 2 16 9 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 1 ² = 67% 6 46 6 48 6 48	0.01 0.01 0.93 [0.66, 13: 0.43 [0.26, 0.7 0.89 [0.39, 207 1.47 [0.76, 2.61 1.09 [0.65, 2.33 0.52 [0.27, 0.98 0.82 [0.62, 1.06 1.57 [1.10, 2.08 0.90 [0.68, 1.19 2.36 [1.05, 5.22 0.94 [0.21, 4.22	Control Favours Favours Fourier SFI fingher S	100 Weigt 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 9.3% 8.7% 56.2% 3.5% 1.3% 5.4%
Chronic GV Study or Subgroup tematologic maligne Cho 2019 Erebena 2009 Konuma 2014 Konuma 2014 Konuma 2014 Lim 2010 Mahindra 2019 Tachibana 2012 Tanaka 2015 Subtotal (85% CI) Total events Heterogeneity: Ch ² = Severe aplastic aner Lin 2022 Pan 2023 Zhang 2017 —	HD higher S Events T 40 15 13 5 13 15 14 4 14 4 14 2 13 7 13 15 14 15 14 2 12 2 13 15 13 5 13 5 13 5 13 5 13 5 13 5 13 15 14 15 14 15 14 15 14 15 14 15 14 15 14 15 14 15 15 15 1	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 2 4 = 0.002); 1 7 7 2	wer SF 9 94 9 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 1 ² = 67% 6 46 6 48 1 69	I Risk Ratio 0.93 (0.66, 1.3) 0.43 (0.26, 0.7) 0.43 (0.26, 0.7) 0.89 (0.38, 2.01) 1.41 (0.76, 2.61 1.00 (0.66, 1.66) 1.43 (0.76, 2.61) 0.82 (0.26, 1.06) 0.82 (0.27, 0.36) 0.82 (0.26, 1.06) 2.36 (1.05, 5.22) 0.94 (0.24, 1.02) 2.36 (1.05, 5.22) 0.94 (0.24, 1.22) 2.36 (1.07, 5.22) 1.34 (0.75, 2.32)	Eavours Favours Favours Favours IowerSFI PigherSFI	100 Weigł 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.1% 4.8% 9.3% 5.6% 3.5% 1.3% 5.4% 5.4%
Chronic GV Study or Subgroup Idmatologic maligne Chancel (Comparison) Ethera 200 Konuna 2014 Konuna 2014 Mahinfa 2009 Mahinfa 2000 Mahinfa 2000 Mahinfa 2000 Mahinfa 2000 Total events Heterogeneity: Chi ² = Severe aplastic aner Lin 2022 Pana 2021 Zhang 2017 Subtotal (9% C1)	HD higher S Events T ancies 40 10 15 4 4 4 4 4 4 4 4 4 4 5 5 3 3 5 13 5 4 4 4 5 4 3 7 10 7 40 12 4 3 3 5 13 4 4 3 7 10 4 8 4 2 4 2 4 2 11 2 11 2 11 4 10 10 10 10 10 10 10 10 10 10 10 10 10	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 4 2 24 = 0.002); 11 7 2 5	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 1 ² = 67% 6 46 6 48 1 69 163	0.01 0.93 (0.66, 1.3) 0.43 (0.26, 0.77 0.88 (0.38, 0.27) 0.89 (0.38, 0.37) 0.45 (0.26, 0.77 0.88 (0.38, 2.67) 0.47 (0.76, 2.64) 0.47 (0.76, 2.64) 0.47 (0.76, 2.64) 0.48 (0.62, 1.06) 0.48 (0.62, 1.06) 0.49 (0.24, 4.22) 1.48 (0.75, 2.26) 0.49 (0.24, 4.22) 0.49 (0.24	Earcord Favours Iover SFI higher SFI	4,100 Weigh 8,4% 6,2% 3,5% 5,0% 6,2% 6,2% 6,2% 6,2% 6,2% 6,2% 6,2% 6,2
Study or Study of Stu	HD higher S Events T ancies 40 10 15 4 4 15 3 10 7 40 8 43 7 53 194 24.23, df = 8 (P mia 28 6 2 1 11 2 11 2 1 11 1 2 1 11 11 2 11	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 5 3 7 6 9 9 4 2 2 4 = 0.002); 11 7 2 5 3	wer SF nts Tota 9 94 2 16 9 16 7 84 5 30 0 46 8 147 7 84 5 30 0 46 8 147 1 109 0 111 653 1 ² = 67% 6 46 6 48 1 69 163 3	Image: 0.01 Image: 0.01 0.93 (0.66, 1.33) 0.43 (0.26, 0.77) 0.89 (0.38, 2.07) 1.41 (0.76, 2.61) 1.02 (0.65, 1.23) 0.52 (0.27, 0.08) 0.82 (0.62, 1.06) 0.82 (0.62, 1.06) 0.82 (0.62, 1.06) 0.82 (0.62, 1.06) 1.34 (0.75, 2.32) 2.36 (1.05, 5.22) 0.49 (0.24, 4.22) 1.35 (0.76, 2.33) 1.55 (0.99, 2.42)	Eavours Favours Evours Favours Evours Favours Evours Favours Favours	4100 Weigi 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 4.8% 9.3% 9.3% 56.2% 3.5% 1.3% 5.4% 10.2%
Chronic GV Study or Subgroup tematologic maligne Cho 2019 Elebera 2009 Konzuna 2014 Konzuna 2014 Konzuna 2012 Lim 2010 Mahindra 2012 Tachbanz 012 Studie events Heterogeneity:Chi ² = Swetre aplastic (9% C) Total events Heterogeneity:Chi ² = Subtotal (9% C) Total events Heterogeneity:Chi ²	HD higher S Events T ancies 40 10 15 40 10 15 5 13 55 13 55 13 57 13 7 40 8 43 7 53 13 54 13 44 44 4 14 4 43 7 43 7 43 7 40 8 43 7 43 7 43 7 43 7 43 7 43 7 43 7 44 1 1 2 1 1 2 8 6 2 1 1 1 2 1 1 2 8 6 2 1 1 2 1 1 2 1 1 2 8 6 2 1 1 2 1 1 2 1 1 2 8 6 2 1 1 2 1 1 2 1 1 2 8 6 2 1 1 1 2 1 2 1 2 1 1 2 8 6 2 1 1 1 1 2 1 1 1 2 8 6 2 1 1 1 2 1 1 2 8 6 2 1 1 1 2 1 1 2 8 6 2 1 1 1 2 1 1 1 1 2 8 6 2 1 1 1 2 1 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1	F Lo otal Eve 4 3 7 1 8 9 1 0 1 3 1 3 1 5 3 7 7 6 9 4 2 24 = 0.002); 7 7 7 2 5 3 ² 8	wer SF 9 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 411 653 1 1 ² = 67% 6 46 6 48 1 69 1 63 3 = 0%	0.01 0.01 0.93 (0.66, 1.3 0.43 (0.26, 0.7 0.89 (0.36, 1.26) 0.45 (0.26, 0.7 0.89 (0.36, 2.6) 0.47 (0.76, 2.61 1.03 (0.55, 0.27, 0.98 0.82 (0.62, 0.94) 0.82 (0.62, 0.94) 0.82 (0.62, 0.94) 0.90 (0.68, 1.19 2.36 (1.05, 5.26) 0.94 (0.21, 4.22 1.34 (0.75, 2.35) 1.55 (0.99, 2.42)		
Study or Study of Study or Study of Stu	HD higher S Events T ancles 40 10 10 4 4 4 4 4 4 15 2 10 7 40 8 43 7 53 104 24.23, df = 8 (P mia 28 6 2 1 11 2 2 1 11 11 2 2 1 11 11 2 2 1 11 11 2 2 2 1 11 11 11 11 11,78, df = 2 (P	F Lo otal Eve 4 3 7 1 8 8 9 1 0 1 3 1 9 4 2 24 2 2 2 4 2 2 7 7 7 7 2 5 5 3 8 9 9 9 4 2 2 4 9 9 4 2 2 4 7 7 1 1 9 9 4 2 2 4 7 7 1 9 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1	wer SF p 94 2 16 9 16 7 84 5 30 0 46 8 147 1 109 0 111 653 1 1 109 0 411 653 1 1 69 163 3 = 0%	0.01 0.39 (0.66, 1.30 0.43 (0.26, 0.77 0.89 (0.39, 2.07 0.89 (0.39, 2.07 0.41 (0.76, 2.61 1.02 (0.65, 2.33 0.52 (0.27, 0.08 0.82 (0.62, 1.06 0.30 (0.66, 1.18 0.20 (0.66, 1.18 0.20 (0.66, 1.19 2.36 (1.05, 5.22 0.94 (0.21, 4.22 1.34 (0.75, 2.33 1.45 (0.75, 2.32 1.45 (0.75, 2.32 1.45 (0.75, 2.32	Eavours Favours [ower SF] pigner SF] pigner SF]	100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3
Study or Subgroup tematologic maligne Cho 2019 Elebera 2009 Konuma 2014 Konuma 2014 Konuma 2014 Konuma 2012 Lim 2010 Mahindra 2029 Tachibana 2012 Tanaka 2013 Subtodal (95% CI) Todal events Heterogeneity:Chi ^a = Subtodal (95% CI) Todal events Heterogeneity:Chi ^a = Both	HD higher S Events T ancies 40 10 15 4 41 4 15 5 13 5 13 13 13 13 13 13 13 13 13 13 13 13 13	F La otal Eve 4 3 7 1 1 8 9 1 0 1 5 3 3 1 5 3 3 1 5 3 3 1 5 3 7 6 6 2 2 4 4 9 4 2 2 2 4 7 7 7 7 7 2 5 3 3 0 2 5 3 7 1 2 2 4 3 2 2 4 4 2 2 4 4 3 2 2 4 3 3 1 2 5 3 5 3 1 5 5 5 6 6 6 6 7 5 7 5 7 5 7 7 1 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	wer SF infts Tota 9 94 2 16 7 84 5 30 46 8 147 1 109 1653 1 1 1° = 67% 6 46 6 48 1 69 163 = 0%	0.01 0.01 0.03 [0.66, 13: 0.43 [0.26, 0.7 0.88 [0.38, 2.07 0.88 [0.38, 2.07 0.45 [0.52, 0.57 0.45 [0.52, 0.58 0.52 [0.52, 0.58 0.52 [0.52, 0.58 0.55 [0.56, 1.59 0.59 [0.55, 2.52 0.54 [0.55, 2.28 1.55 [0.99, 2.42	D.1 1 10 Favours Favours IoverSPI prigherSFI	100 Weigh 8.4% 6.2% 5.0% 6.2% 6.2% 6.2% 6.2% 6.2% 4.1% 5.6% 5.6% 5.6% 5.4% 10.2%
Chronic GV Study or Subgroup Hematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kupesiz 2020 Um 2010 Mahirdra 2009 Tanika 2015 Subtotal (95% CI) Total events Heterogeneity:ChP = Severe aplastic aner Lin 2022 Pan 2023 Zhang 2017 Subtotal (95% CI) Total events Heterogeneity:ChP = Both Al Malai 2020	HD higher S Events T ancies 10 10 14 4 14 4 15 3 13 5 10 7 40 8 43 7 5 10 7 40 8 43 7 13 40 8 43 7 14 24.23, df = 6(1) 11 2 2 11 11 2 2 11 11,76, df = 2 (P+ 10 2)	F Lo 4 3 7 1 9 1 3 1 3 1 3 2 4 3 7 2 7 2 7 2 3 3 6.0.41); P 0.41); P	wer SF 9 94 2 16 7 84 5 7 84 5 7 84 6 46 6 46 6 46 6 46 1 69 163 3 = 0% 2 73	0.01 0.01 0.93 [0.66, 13: 0.43 [0.26, 0.77 0.89 [0.39, 2.07 1.41 [0.76, 2.61 1.03 [0.55, 2.33 0.52 [0.27, 0.98 0.82 [0.62, 1.06 0.90 [0.68, 119 2.36 [1.05, 5.22 0.94 [0.21, 4.22 1.34 [0.75, 2.23 1.35 [0.59, 2.42 0.76 [0.46, 1.22]		100 Weigh 8.4% 6.2% 3.5% 5.0% 6.2% 4.1% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3
Study or Subgroup tematologic maligne Cho 2019 Elebera 2009 Konuma 2014 Konuma 2014 Konuma 2014 Kupesiz 2020 Lim 2010 Mahindra 2029 Tachibana 2012 Tanaka 2019 Subtotal (85% CI) Total events Heterogeneity:ChP = Both Al Malia (2020	HD higher S Events T ancles 40 10 15 4 41 4 16 5 10 7 40 5 10 7 43 5 10 4 43 5 10 7 40 7 43 5 10 7 10 7 40 7 43 5 10 7 10 7 40 7 43 5 10 7 10 7 43 5 10 7 10 7 43 5 10 7 10	F Lot total Eve 4 3 3 8 9 1 3 1 7 6 9 9 4 2 2 4 2 2 4 2 1 7 7 5 3 8 0 - 0,002); 1 7 7 2 3 4 4 3 4 1 3 4 1 4 3 4 4 3 4 4 4 3 4 4 4 5 5 3 5 3 4 4 4 5 5 3 3 5 3 3 3 4 2 2 4 5 3 3 3 4 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1	wer SF 9 94 9 16 9 16 9 16 9 16 9 16 9 16 9 16 9 16	0.01 0.01 0.03 (0.66, 1.3 0.43 (0.26, 0.7 0.48) (0.38, 2.07 0.48) (0.38, 2.07 0.48) (0.38, 2.07 1.04) (0.66, 1.64 1.13) (0.55, 2.35 0.52 (0.27, 0.59 0.32 (0.65, 1.52 0.39 (0.65, 1.52 0.39 (0.65, 1.23 0.39 (0.65, 2.35 1.55 (0.99, 2.42 0.76 (0.46, 1.22 1.27 (0.66, 2.35	Eavours Fervours Evours Fervours Evours Fervours Evours Evours Fervours Fervours	100 Weigł 8.4% 6.2% 3.5% 6.2% 3.5% 5.0% 6.2% 4.1% 4.8% 9.3% 5.6% 5.6% 5.4% 10.2% 6.2% 5.0% 9.3%
Chronic GV Study or Subgroup Jematologic maligne Cho 2019 Elebera 2009 Kim 2008 Konuma 2014 Kupesiz 2020 Um 2010 Mahindra 2009 Subtotal (8% C) Total events Heterogeneity:Chi [#] = Severs aplastic aner Lin 2022 Subtotal (8% C) Total events Heterogeneity:Chi [#] = Both Al Maki 2020 Fingut 2021	HD higher S Events T ancies nancies 15 40 10 15 4 4 4 15 3 13 5 13 5 13 5 14 24.23, df = 8 (P mia 28 5 2 1 13 14 24.23, df = 8 (P mia 1.78, df = 2 (P ⁻¹) 10 2 29 11 53 12	F La total Eve 4 3 7 4 3 7 9 1 1 7 1 5 3 7 7 2 2 24 4 2 2 24 5 3 6 0.41); P 3 4 1 2 5	wer SF 9 94 2 16 9 94 5 30 0 46 5 30 0 41 1 = 67% 2 = 67% 3 = 0% 2 = 73 1 = 5% 2 = 73 5 = 5% 2 = 75% 2	0.01 0.01 0.93 [0.66, 1.32 0.43 [0.26, 0.77 0.89 [0.38, 2.07 0.89 [0.38, 2.07 1.41 [0.76, 2.61 1.03 [0.56, 2.33 0.52 [0.27, 0.68 0.80 [0.66, 1.12 1.51 [1.10, 2.06 0.90 [0.66, 1.12 1.56 [0.96, 2.42 1.56 [0.96, 2.42 1.56 [0.96, 2.42 0.76 [0.46, 1.22 1.27 [0.65, 1.23 0.97 [0.66, 1.25 0.97 [0.66, 1.25] 0.97 [0.96] 0.97 [0.9		100 Weigi 8.4% 6.2% 3.5% 4.1% 4.8% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3% 9.3
Chronic GV Study or Subgroup Iematologic maligne Cho 2019 Elebera 2009 Konuma 2014 Kine 200 Konuma 2014 Kine 2010 Lim 2010 Mahindra 2009 Tanka 2014 Subtotal (95% CI) Total events Heterogeneity:ChP = Subtotal (95% CC) Total events Heterogeneity:ChP = Subtotal (25% CC) Total events Heterogeneity:ChP = Subtotal (222 Total 221 Kataoka 2209 Sakamoto 2013	HD higher S Events T notes 40 fC 4 4 15 4 4 15 5 10 7 40 fC 4 13 5 10 7 40 fC 4 14 4 4 15 5 10 7 40 fC 4 13 2 13 2 14 4 4 14 4 4 15 5 10 7 40 5 10 7 10 7 40 5 10 7 10 7	F Lo total Eve 44 3 3 10 1 33 1 17 6 9 4 2 24 2 4 2 4 2 4 3 4 4 1 1 6 3 4 4 1 1 6 1 6 1 6 1 6 1 6 1 7 1 7 1 8 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	wer SF 9 94 9 16 9 16 9 16 9 16 9 16 9 16 9 16 9 16 9 10 9 16 9 16 9 16 9 16 9 16 9 16	Image: 100 minipage Image:	Eavours Favours [owerSF] Product SF]	
Chronic GV Study or Subgroup Hematologic maligni Che 2019 Efshera 2009 Kim 2009 Kim 2009 Kim 2009 Kim 2009 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (5% C1) Total events Heterogeneity:ChP = Sovere aplastic aner Lin 2022 Plan 2023 Zhang 2017 Total events Heterogeneity:ChP = Southotal (5% C1) Total events Heterogeneity:ChP = Both Al Malki 2020 Fingut 2021 Sakamoto 2013 Sakamoto 2013	HD higher S Events T nncles nncles 15 40 10 15 41 4 4 15 5 13 5 13 5 13 5 14 24.23, df = 8 (P nia 28 5 2 11 11 1 24 1 14 2 4 24,23, df = 2 (P-1) 10 2 29 11 53 15 4 7 15 24 7 15 54 7 15 55 16 7 10 7 1	F Lo otal Eve 4 3 7 1 8 8 0 1 1 3 1 1 7 6 8 9 1 9 1 0 1 1 3 1 7 7 6 2 2 4 4 2 2 2 4 3 4 1 2 2 5 5 3 3 4 1 2 2 5 1 1 7 1 1 8 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	wer SF 9 94 2 16 9 94 5 30 0 46 5 30 0 411 6 5 3 3 1 10 6 5 3 3 1 10 7 5 4 5 30 1 10 10 11 1 65 3 3 1 10 10 11 1 65 3 3 1 10 10 11 1 65 3 3 1 10 10 11 1 10 10 11 1 1 5 5 3 3 1 3 2 5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	0.01 0.01 0.93 [0.66, 13: 0.43 [0.26, 0.7 0.89 [0.38, 2.07 0.89 [0.38, 2.07 0.89 [0.38, 2.07 0.89 [0.38, 2.07 1.41 [0.76, 2.61 1.13 [0.55, 2.33 0.52 [0.27, 0.68 0.82 [0.62, 1.06 1.51 [1.10, 2.06 0.90 [0.66, 1.12 2.36 [1.05, 5.22 1.34 [0.75, 2.25 1.55 [0.49, 2.42 1.34 [0.75, 2.25 1.55 [0.49, 2.42 1.57 [0.46, 1.22 1.27 [0.69, 2.42 0.76 [0.46, 1.22 1.27 [0.69, 2.42 0.76 [0.46, 1.22 1.27 [0.68, 1.27 0.69 [0.46, 1.25 0.76 [0.44, 1.32 0.76 [0.44, 1.32		
Study or Subgroup Itematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kuipesz 2020 Lim 2010 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (95% CI) Total events Heterogeneily:Ch ² = Severe aplastic aner Lin 2022 Pan 2023 Zhang 2017 Subtotal (95% CI) Total events Heterogeneily:Ch ² = Both An Malia 2020 Filingut 2021 Subtotal (95% CI) Total events Heterogeneily:Ch ² = Both	HD higher S Events T notes 40 10 15 40 10 15 41 44 4 15 3 13 55 10 7 40 52 10 7 40 52 13 42 14 44 15 3 13 55 10 7 40 52 19 43 24 23, df = 8 (P 11 2 2 1 11 2 2 1 11 1 2 2 11 1 2 2 11 1 2 2 11 1 2 2 11 1 15 5 2 3 11 5 2 1 11 1 2 1 2	F Lo total Eve 44 3 10 1 10 1 13 1 10 1 13 1 10 1 1	wer SF mints Tota 9 94 2 16 9 16 7 84 5 30 46 8 147 1 109 1653 1 1653 6 46 6 48 147 1653 1 163 3 3 1 55 8 132 2 73 1 55 8 132 2 73 4 33 4 3 4	0.01 0.01 0.93 (0.66, 1.33 0.43 (0.26, 0.77 0.89 (0.38, 2.07 0.89 (0.38, 2.07 1.41 (0.76, 2.61 1.13 (0.55, 2.33 0.52 (0.27, 0.08 0.80 (0.64, 1.10 0.49 (0.24, 1.22 1.41 (0.75, 2.35 1.45 (0.49, 2.42 1.45 (0.75, 2.35 1.45 (0.49, 2.42 0.76 (0.46, 1.22 1.47 (0.75, 2.35 1.45 (0.49, 2.42 0.76 (0.46, 1.22 1.47 (0.75, 2.35 1.45 (0.49, 2.42 0.76 (0.46, 1.22 1.47 (0.75, 2.35 0.47 (0.76, 1.22 0.47 (0.76, 1.42 0.47 (0.46, 1.22 0.47 (0.46, 1.22	Eavours Favours Evours Favours Evours Favours Evours Favours Favo	
Chronic GV Study or Subgroup Icma 2019 Icma 2019 Icma 2019 Icma 2019 Icma 2019 Icma 2019 Icma 2010 Mahindra 2009 Icma 2010 Mahindra 2009 Subtotal (95% C) Total events Heterogeneity: ChP = Southoral (95% C) Total events Heterogeneity: ChP Both Heterogeneity: ChP Both A Mahit 2020 Fingut 2021 Subtotal (95% C) Total events Heterogeneity: ChP Both Ictanoba 2009 Salamoto 2013 Salarda 2009 Salamoto 2013 Subtotal (95% C) Total events Heterogeneity: ChP Ictanoba 2009 Salamoto 2013 Subtotal (95% C) Total events	HD higher S Events T ancles 10 40 10 15 40 10 15 3 13 5 5 10 7 40 8 43 7 31 5 5 10 7 40 8 43 7 31 8 6 2 11 11 2 11 12 14 14 4 14 4 15 3 18 8 6 2 11 12 11 12 14 12 14 2423, df = 8 (P nia 2 2 5 11 2 11 12 12 14 12 25 11 2 13 5 14 2423, df = 8 (P 10 2 2 5 11 2 11 2 11 2 12 14 12 25 13 3 14 24 14 24 14 4 15 3 16 4 16 4 17 3 16 4 16 4 17 4 16 4 17 4 16 4 17 4 16 4 16 4 16 4 17 4 16 4 17 4 16 4 16 4 17 4 16 4 16 4 17 4 16 4 16 4 17 4 16 4 17 4 16 4 17 4 16 4 16 4 17 4 17 4 16 4 17 4 16 4 17 4 16 4 17 4 16 4 17 4 16 4 17 4 17 4 16 4 17 4 16 4 17 4	F Lo otal Eve 34 3 47 1 8 8 10 1 135 3 7 6 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1	war SF infts Tota 2 16 9 16 9 16 5 30 46 6 46 8 147 1 69 0 111 9 67% 6 46 6 48 1 69 1 63 3 3 3 3 3 3 3 33 3 33 3 33 4 33	0.01 0.01 0.93 (0.66, 1.30 0.43 (0.26, 0.77 0.88 (0.38, 2.07 0.88 (0.38, 2.07 0.88 (0.38, 2.07 0.48 (0.26, 2.07 0.48 (0.26, 2.07 0.48 (0.26, 2.06 0.49 (0.26, 1.42 0.49 (0.26, 1.42 1.34 (0.75, 2.35 1.35 (0.39, 2.42 0.49 (0.26, 1.22 1.34 (0.75, 2.35 1.35 (0.39, 2.42 0.49 (0.26, 1.22 1.27 (0.66, 1.22 1.27 (0.66, 1.22 1.27 (0.66, 1.22 1.27 (0.66, 1.22 0.59 (0.46, 1.25) 0.75 (0.44, 1.38 0.74 (0.76, 1.04) 0.75 (0.44, 1.38 0.74 (0.76, 1.04) 0.75 (0.44, 1.38) 0.75 (0.44, 1.38) 0	Earours Favours IowerSFI higherSFI	
Chronic GV Study or Subgroup dematologic maligne Cho 2019 Efebora 2009 Kim 2008 Konuma 2014 Kuipesiz 2020 Lim 2010 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (95% C) Total events Heterogeneity:Ch ² = Severe aplastic aner Lin 2022 Pan 2023 Zhang 2017 Subtotal (95% C) Total events Heterogeneity:Ch ² = Both Al Malia 2020 Sakamoto 2013 Sakamoto 2014 Sakamoto 2014 Sakamoto 2014 Sakamoto 2014	HD higher S Events T ancies 10 10 14 4 15 3 13 55 10 7 40 55 10 7 40 55 10 7 40 55 13 55 13 55 14 4 4 24.23, df = 6 (P 11 2 29 11 53 15 24 1 15 39 11 2 29 11 53 15 24 1 15 39 15 39 1	F Lo otal Eve 7 3 7 1 8 9 1 0 1 5 3 7 6 6 9 4 2 2 4 2 2 4 5 3 7 6 6 9 4 2 2 4 1 1 7 7 2 2 5 3 3 4 4 1 1 6 6 1 1 1 6 6 1 1 9 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	wer SF mits Tota 9 94 2 16 9 16 7 84 5 30 46 8 147 1 109 1653 1 165 6 46 6 48 147 6 46 6 48 163 3 1 55 8 132 2 73 1 55 8 132 2 73 3 1 55 8 133 3 = 00%	Image: 100 minipage Risk Ratio 0.93 [0.66], 13: 0.43 [0.26, 0.77 0.89 [0.38, 2.07 0.88 [0.38, 2.07 0.41 [0.76, 2.61 1.00 [0.65, 1.62 0.45 [0.37, 2.07 0.88 [0.38, 2.07 0.45 [0.47, 0.46, 1.26 0.49 [0.26, 1.27 0.46 [0.46, 1.26 0.49 [0.46, 1.26 0.46 [0.46, 1.27 1.41 [0.76, 2.35 0.46 [0.46, 1.27 1.41 [0.47, 2.36 0.47 [0.46, 1.27 1.42 [0.46, 1.21 0.47 [0.46, 1.26 0.49 [0.46, 1.26 0.47 [0.46, 1.26 0.41 [1.36 0.47 [0.44, 1.36 0.44 [0.76, 1.61	Eavours Favours [ower SF] higher SF]	
Chronic GV Study or Subgroup tematologic malligne Cho 2019 Elebera 2009 Konzuna 2014 Konzuna 2014 Konzuna 2012 Lim 2010 Mahindra 2002 Lim 2010 Subtal (9% C) Tobi events Heterogeneity:Chi ^a = Subtal (9% C) Tobi events Heterogeneity:Chi ^a = Subtal (9% C) Tobi events Heterogeneity:Chi ^a = Subtal (9% C) Tobi events Heterogeneity:Chi ^a Subtal (202) Finguti 2021 Subtal (202) Subtal	HD higher S Events T ancles 40 10 15 40 10 15 5 13 56 10 7 40 16 13 56 13 56 13 66 14 4 14 4 14 4 14 4 14 4 14 4 14 7 13 6 13 6 13 6 13 6 13 6 14 7 13 6 13 6 14 7 13 6 13 6 13 6 13 7 13 6 14 7 13 6 13 7 13 6 14 7 13 7 13 6 14 7 14 7 13 6 13 7 13 8 14 7 14 14 14 4 14 4 13 7 13 8 14 1 14 12 11 2 11 12 11 12 1	F Loc otal Eve 4 3 7 1 8 9 1 5 3 1 5 3 1 5 2 2 4 7 7 7 2 2 2 4 7 7 7 5 5 8 0.41); P 7 3 4 4 1 1 8 0 0 7 1 5 3 3 4 4 4 1 1 9 9 9 9 9 9 9 1 9 9 1 9 9 1 7 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 5 5 5 5	$\begin{array}{c} \text{wwar SF} \\ \text{ints Tota} \\ 9 & 94 \\ 2 & 16 \\ 9 & 16 \\ 9 & 16 \\ 5 & 30 \\ 46 \\ 8 & 147 \\ 7 & 84 \\ 5 & 30 \\ 0 & 68 \\ 1 & 109 \\ 0 & 111 \\ 109 \\ 0 & 111 \\ 163 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\$	0.01 0.01 0.93 (0.64, 1.32 0.43 (0.26, 0.77 0.88 (0.38, 2.07 0.88 (0.38, 2.07 0.88 (0.38, 2.07 0.48 (0.26, 0.77 0.88 (0.38, 2.07 0.48 (0.26, 1.27 0.48 (0.26, 1.26 0.90 (0.69, 1.19 0.90 (0.69, 1.24 1.34 (0.75, 2.35 1.55 (0.99, 2.42 1.34 (0.75, 2.35 1.55 (0.99, 2.42 0.76 (0.46, 1.24 0.76 (0.41, 1.35 0.34 (0.70, 1.01	Eavours Fervours Evours Fervours Evours Fervours Evours Evours Fervours Evours Fervours Fervours	
Chronic GV Study or Subgroup Jematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Kubesiz 2020 Lim 2010 Mahindra 2009 Tanaka 2015 Subtotal (95% CI) Total events Heterogeneity:ChP = Both Heterogeneity:ChP = Both Al Malai 2020 Fingut 2021 Subtotal (95% CI) Total events Heterogeneity:ChP = Both Al Malai 2020 Sakamoto 2013 Sakatoka 2009 Sakamoto 2013 Subtotal (95% CI) Total events Heterogeneity:ChP = Subtotal (95% CI) Subtotal (95% CI) Subtot	HD higher S Events T ancies 15 40 10 15 3 13 55 10 7 40 8 414 4 15 3 13 5 13 5 13 5 14 4 24.23, df = 2 (P- 11 2 2 9 11 53 15 24 7 15 2 (P- 10 2 2 9 11 53 15 24 7 15 2 (P- 15 3 3 3.56, df = 4 (P- 15 3 13 13 13 13 15 13 13 15 13 13 13 15 13 13 13 15 13 13 15 13 13 13 13 13 13 13 15 15 15 15 15 15 15 15 15 15 15 15 15	F Lo otal Eve 3 7 1 8 9 1 0 1 5 3 1 5 3 1 5 5 2 2 4 4 5 5 3 7 6 0.41); I ² 7 3 4 4 1 1 6 9 9 4 9 2 2 4 1 7 3 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 3 3 1 1 5 5 3 1 1 5 5 3 1 1 5 5 3 1 1 5 5 3 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 3 1 1 1 5 5 5 3 1 1 1 1	war SF ints Tota 9 94 2 16 8 147 7 84 8 147 7 84 8 147 1 109 0 111 1 109 0 111 1 109 0 111 1 109 0 111 1 109 0 111 1 653 3 3 = 0% 2 73 3 3 3 3 = 0%	0.01 0.01 0.93 [0.66, 13: 0.43 [0.26, 0.7 0.48 [0.38, 2.07 0.48 [0.38, 2.07 0.48 [0.38, 2.07 0.49 [0.38, 2.07 0.49 [0.36, 2.33 0.52 [0.27, 0.98 0.82 [0.62, 1.06 0.90 [0.68, 1.19 2.36 [1.05, 5.22 0.94 [0.21, 4.22 1.34 [0.75, 2.33 1.55 [0.99, 2.42 0.76 [0.46, 1.22 1.27 [0.68, 2.33 0.57 [0.68, 1.21 0.96 [0.46, 1.22 1.27 [0.68, 2.33 0.91 [0.66, 1.21 0.57 [0.44, 1.32 0.57 [0.44, 1.32 0.57 [0.44, 1.32 0.54 [0.76, 1.01 0.53 [0.74, 1.12] 0.53 [0.74, 1.12] 0.54 [0.74, 1.12] 0.54 [0.74, 1.12] 0.54 [0.74, 1.12] 0.55 [0.7	Eavours Favours [ower SF] higher SF]	
Study or Subgroup tematologic maligne Cho 2019 Elebera 2009 Konuma 2014 Konzola Lim 2010 Lim 2010 Mahindra 2009 Tachibana 2012 Tanaka 2019 Subtotal (95% CI) Total events Heterogeneity:Chi ^a = Subtotal (95% CI) Total events Heterogeneity:Chi ^a = Total (95% CI) Total events	HD higher S Events T notes 40 fc 4 4 15 3 13 5 10 7 40 fc 4 4 15 4 10 7 40 fc 4 13 2 13 2 14 4 4 2 1 13 2 2 1 14 4 4 2 2 1 1 1 24.23, df = 8 (P 10 2 2 1 1 1 2 8 1 2 9 1 1 3 3 5 3 1 2 1 1 1 5 3 1 5 2 1 1 1 5 2 1 1 1 5 2 1 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 5 5 1 1 1 2 5 1 1 1 1 2 5 1 1 1 1 2 5 1 1 1 1 2 5 1 1 1 1 2 5 1 1 1 2 5 1 1 1 2 5 1 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 5 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 2 1 1 1 3 1 1 1 3 1 3 1 3 1 1 1 3 1 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	F Loc otal Eve 4 3 7 1 8 9 1 5 3 1 5 3 1 5 2 2 4 7 7 2 2 2 4 7 7 7 5 5 8 0.41; P 7 3 4 4 1 1 9 9 9 4 4 1 7 7 1 8 9 9 1 9 9 4 7 1 5 3 1 1 5 3 1 1 5 3 1 1 5 3 1 1 5 3 1 1 5 3 1 7 1 5 3 1 1 1 5 3 1 1 5 3 1 1 5 3 1 1 1 5 3 1 1 5 3 1 1 1 5 3 1 1 5 3 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 3 1 1 1 5 5 5 5	$\begin{array}{c} \text{wer SF} \\ \text{mms} \ \text{Tota} \\ \text{9} \ \ 94 \\ 2 \ \ 16 \\ \text{7} \ \ 84 \\ \ 84 \\ \text{7} \ \ 84 \\ \ 84 \\ \ 84 \ \ 84 \\ \ 84 \ \ 84 \\ \ 84 \ \ $	Image: 100 minipage Risk Ratio 0.93 [0.66], 13. 0.43 [0.26, 0.77 0.89 [0.38, 2.07 0.88 [0.38, 2.07 0.89 [0.36, 1.12 0.76 [0.46, 1.12 0.20 [0.66, 1.13 0.65, 2.33 0.82 [0.27, 0.36 0.82 [0.27, 0.36 0.39 [0.66, 1.19 0.39 [0.66, 1.19 2.36 [1.05, 5.22 0.94 [0.24, 4.22 0.76 [0.46, 1.22 1.36 [0.39, 2.42 0.76 [0.46, 1.22 0.27 [0.41, 1.36 0.84 [0.70, 1.01 0.83 [0.78, 1.12	Eavours Favours [owerSF] Profer SF]	
Chronic GV Study or Subgroup Hematologic maligne Cho 2019 Elebera 2009 Kim 2009 Kim 2009 Kim 2004 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (8% C) Total events Heterogeneity:Chi ² = Soutora ajlastic aner Lin 2022 Pan 2023 Zhang 2017 Subtotal (8% C) Total events Heterogeneity:Chi ² = Both Al Malki 2200 Fingut 2021 Subtotal (8% C) Total events Heterogeneity:Chi ² = Stotal (8% C) Total events Heterogeneity:Chi ² = Stotal (8% C) Total events Heterogeneity:Chi ² = Subtotal (8% C) Total events Heterogeneity:Chi ² = Total events	HD higher S Events T nucles 15 40 10 15 41 4 4 15 3 13 55 10 7 40 85 10 7 40 85 10 7 40 85 10 7 40 85 2 1 10 7 40 85 2 2 11 12 14 2 2 1 13 2 2 1 13 14 2 4 23, df = 6 (P) 10 2 2 9 11 15 3 3 3.68, df = 4 (P) 10 5 3 3.78, df = 4 (P) 10 5 10 5	F Lo. total Eve 4 3 7 1 1 9 1 3 7 6 9 2 4 2 24 9 4 2 24 1 0 1 3 7 6 9 9 4 2 24 1 7 2 3 4 2 1 7 2 3	wars SF inits Tota 9 94 2 166 7 84 8 147 7 84 1 109 0 111 1 17 1 653 3 46 46 46 48 147 1 109 0 111 1 17 1 653 3 3 2 73 3 3 3 3 3 3 3 3 3 3 7 1249 7	0.01 0.01 0.93 [0.61, 13: 0.43 [0.26, 0.77 0.89 [0.39, 2.07 0.89 [0.39, 2.07 1.41 [0.76, 2.61 1.03 [0.55, 2.33 0.52 [0.27, 0.68 0.89 [0.68, 1.19 2.36 [1.05, 5.22 1.34 [0.76, 2.32 1.34 [0.76, 2.32 1.34 [0.76, 2.32 1.35 [0.99, 2.42 0.76 [0.46, 1.22 1.27 [0.69, 2.32 0.97 [0.66, 1.21 0.97 [0.46, 1.22 1.27 [0.69, 2.32 0.97 [0.46, 1.22 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.97 [0.46, 1.22] 0.		100 Weigh 8,4% 8,5% 5,5% 8,2% 8,3% 8,5% 8,5% 10,2% 6,2% 3,5% 10,2% 10,2% 10,0%
Study or Subgroup Study or Subgroup Itematologic maligne Cho 2019 Efebera 2009 Kim 2008 Konuma 2014 Küpesiz 2020 Lim 2010 Mahindra 2009 Tachibana 2012 Tanaka 2015 Subtotal (95% CI) Total events Heterogeneily:ChP = Both Al Malii 2020 Fingnt 2021 Subtotal (95% CI) Total events Heterogeneily:ChP = Both Al Malii 2020 Fingnt 2021 Subtotal (95% CI) Total events Heterogeneily:ChP = Total (95% CI)	HD higher S Events T notes 40 ft 4 4 15 4 13 5 10 7 40 5 10 7 40 5 13 4 4 14 4 5 10 7 40 7 13 4 24 23, df = 8 (P 11 2 24 1 11 12 29 11 11 12 29 11 11 1 29 11 13 1 29 11 13 5 13 5 13 5 14 4 10 7 40 7 194 20 2 11 1 11 2 20 1 11 5 20 7 15 5 10 7 10 7	$\begin{array}{cccc} F & Lo \\ table & La \\$	wer SF 9 94 2 16 9 94 2 16 5 30 0 46 5 30 4 653 1 109 163 3 3 3 2 73 1 59 163 3 3 33 3 33 3 33 1249 9 100 1249 9 90% 1249 10% 1249 10% 1249 10% 1249 10% 1249 10%	Image: 100 minipage Risk Ratio 0.93 [0.66], 13. 0.43 [0.26, 0.77 0.89 [0.39, 2.07] 0.48 [0.38, 2.07] 1.41 [0.76, 2.61] 1.05 [0.55, 2.33] 0.52 [0.27, 0.68] 0.82 [0.62, 1.06] 1.54 [0.76, 2.61] 0.90 [0.66], 1.19] 2.36 [1.05, 5.22] 0.94 [0.24, 1.22] 1.45 [0.96], 2.33 1.45 [0.96], 2.34 0.76 [0.46, 1.22] 1.46 [0.76, 2.33] 0.76 [0.46, 1.22] 1.27 [0.66], 2.34 0.76 [0.46, 1.22] 1.26 [0.76, 2.34] 0.76 [0.46, 1.24] 0.68 [0.76, 1.01] 0.93 [0.78, 1.12] 0.33 [0.78, 1.12]	Eavours Favours [owerSF] Product SF]	

C. Sinusoidal obstruction syndrome

	group Events Total		Iower SF Events Total			Favoura	Payours	
Study or Subgroup					Risk Ratio	[lower SF]	[higher SF]	Weight
Hwang 2016	8	46	2	86	7.48 [1.66, 33.77]			9.0%
Kim 2008	1	16	1	22	1.38 [0.09, 20.38]		•	4.2%
Kloehn 2022	12	50	3	41	3.28 [0.99, 10.85]			11.1%
Kuipesiz 2020	5	30	3	30	1.67 [0.44, 6.36]		-	10.1%
Mahindra 2009	62	75	125	147	0.97 [0.86, 1.10]			18.1%
Maradei 2009	43	137	45	290	2.02 [1.40, 2.91]			17.2%
Maximova 2014	20	72	14	128	2.54 [1.37, 4.72]			15.6%
Suck 2010	37	106	7	42	2.09 [1.01, 4.32]		-	14.7%
Total (95% CI)		532		786	2.11 [1.12, 3.98]		~	
Total events	188		200				\sim	100.0%
Heterogeneity: Chi ² = 6	30.59, df = 1	7 (P < 0	.00001);	l² = 88%				
					0.01	0.1 1	10	100

Fig. 4. Forest plots illustrating study specific and pooled risk ratio (RR) and 95 % confidence interval (CI) for the effect of a higher serum ferritin (SF) level vs a lower SF level. **A:** Grade II-IV acute GVHD, grouped by disease type (hematological malignancies, severe aplastic anemia, or both); **B:** chronic GVHD, grouped by disease type (hematological malignancies, severe aplastic anemia, or both); **C:** hepatic sinusoidal obstruction syndrome.

A. Infection



B. Fungl infection

	Highe	er SF	Lower	r SF		F	Farran		
Study	Events	s Total	Events	Total	Risk Ratio	[lower SF]	[higher SF]		Weight
Dadwal 2015	14	220	7	257	2.34 [0.96, 5.69]				11.2%
Ozvilmaz 2010	15	89	7	54	1.30 [0.57, 2.98]				15.1%
Sucak 2010(allo)	43	102	12	46	1.62 [0.94, 2.76]		_		28.6%
Sucak 2010(auto)	7	28	7	74	2.64 [1.02, 6.86]				6.6%
Tanaka 2015	6	79	7	111	1.20 [0.42, 3.45]				10.1%
Wermke 2012	8	33	10	55	1.33 [0.59, 3.04]		-		13.0%
Zhang 2017	7	27	16	69	1.12 [0.52, 2.41]				15.6%
Total (95% CI)		578		666	1.56 [1.16, 2.10]		\diamond		100.0%
Total events	100		66				Ť		
Heterogeneity: Chi2	² = 3.26,	df = 6 (F	e = 0.78);	l² = 0%	0.01 0	.1	1 1	0 100	

C. Bacterial infection

Chudy	Highe	r SF	Low	er SF			-	_		
Study	Events Total		Events Total		Risk Ratio		Favours Favours [lower SF] [higher SF]			Weight
Kanda 2011	14	47	4	49	3.65 [1.29, 10	.29]				7.8%
Tanaka 2015	32	79	49	111	0.92 [0.65, 1	.29]	-	-		31.6%
Wermke 2012	19	33	31	55	1.02 [0.70, 1	.48]	-	-		29.3%
Zhang 2017	17	27	42	69	1.03 [0.73, 1	.46]	-	-		31.2%
Total (95% CI)		186		284	1.09 [0.80, 1	.50]	•			100.0%
Total events	82		126							
Heterogeneity: Chi ²	² = 6.42,	df = 3 (F	P = 0.09	9); l² = 53%						
					0.01	0.1		1 10	100	

Fig. 5. Forest plots illustrating study specific and pooled risk ratio (RR) and 95 % confidence interval (CI) for the effect of a higher serum ferritin (SF) level vs a lower SF level. A: extensive infection; B: fungal infection; C: bacterial infection.

3.3. Sensitivity analysis and publication bias

To ensure the robustness of our findings for OS, DFS, NRM, relapse rates, aGVHD, cGVHD, infection, and causes of mortality, sensitivity analyses were conducted by omitting one study at each turn. Overall, the sensitivity analyses revealed no alteration in the significance or direction of effect for the association between the pre-transplantation SF level and OS, DFS, NRM, relapse, aGVHD, cGVHD, SOS, infection, or causes of death, suggesting that the overall combined risk estimates were robust.

Egger and Begg tests were conducted along with funnel plots to evaluate potential publication bias in our meta-analysis. Funnel plots indicated no apparent publication bias for DFS (Begg test: p = 0.974; Egger test: p = 0.099; Supplementary Fig. 1), relapse (Begg test: p = 0.499; Egger test: p = 0.494; Supplementary Fig. 2), aGVHD (Begg test: p = 0.112; Egger test: p = 0.363; Supplementary Fig. 3), or cGVHD (Begg test: p = 0.303; Egger test: p = 0.773; Supplementary Fig. 4); however a significant publication bias was observed for OS (Begg test: p = 0.150; Egger test: p = 0.001; Supplementary Fig. 5) and NRM (Begg test: p = 0.234; Egger test: p = 0.024; Supplementary Fig. 6).

A trim-and-fill analysis was conducted to assess the impact of potential publication bias on OS and NRM in our meta-analysis. For OS, adding 17 missing studies led to total of 64 included studies, and for NRM, adding 5 missing studies led to a total of 24 included studies. The updated funnel plots for publication bias regarding the association of the SF level with OS (Supplementary Fig. 7) and NRM (Supplementary Fig. 8) appeared to be relatively symmetrical. Importantly, the updated pooled HRs remained largely unchanged: 1.53 (95 % CI: 1.38–1.69; p < 0.001) for OS and 1.555 (95 % CI: 1.309–1.846; p < 0.001) for NRM. This suggests that the pooled HRs for OS and NRM in our meta-analysis remained stable.

A. Deaths due to relapse or disease progression





B. Deaths due to infection

	Higher	· SF	Lower SF			Favours	Favours		
Study	Events	Total	Events	Total	Risk Ratio	[lower SF]	[higher SF]		Weight
Chee 2017	22	318	14	280	1.38 [0.72, 2.65]	-			37.6%
Efebera 2009	9	47	2	16	1.53 [0.37, 6.36]				7.5%
Kataoka 2009	19	132	6	132	3.17 [1.31, 7.68]		e		15.2%
Mahindra 2009	9	75	6	147	2.94 [1.09, 7.95]		_		10.2%
Pan 2023	6	17	5	48	3.39 [1.19, 9.68]				6.6%
Penack 2019	14	145	5	153	2.95 [1.09, 8.00]		_		12.3%
Tanaka 2015	7	79	5	111	1.97 [0.65, 5.97]	_			10.5%
Total (95% CI)		813		887	2.21 [1.55, 3.15]		\diamond		100.0%
Total events	86		43				Ť		
Heterogeneity: Ch	ni ² = 4.20,	df = 6	(P = 0.65); I ² = 0%	, i i i i i i i i i i i i i i i i i i i				
0,					0.01	0.1	1 10	100	

C. Deaths due to GVHD

	Higher	SF	Lower	SF			Favours	Favours		
Study	Events	Total	Events	Total	Risk Ratio		[lower SF]	[higher SF]		Weight
Chee 2017	19	318	14	280	1.19 [0.61, 2.34	4]	_	-		36.7%
Efebera 2009	1	47	0	16	1.06 [0.05, 24.86	5]				1.8%
Kataoka 2009	9	132	5	132	1.80 [0.62, 5.23	3]				12.3%
Kuipesiz 2020	3	30	1	30	3.00 [0.33, 27.23	3]				2.5%
Mahindra 2009	10	75	22	147	0.89 [0.45, 1.78	3]	_	<u> </u>		36.6%
Pan 2023	0	17	1	48	0.91 [0.04, 21.27	7]				2.0%
Tanaka 2015	3	79	4	111	1.05 [0.24, 4.58	3]				8.2%
Total (95% CI)		698		764	1.18 [0.79, 1.77	1				100.0%
Total events	45		47							
Heterogeneity: Ch	ni² = 1.98,	df = 6	(P = 0.92); l ² = 09	% ⊢					4
					0	.01	0.1	1	10 100	Ď

Fig. 6. Forest plots illustrating study specific and pooled risk ratio (RR) and 95 % confidence interval (CI) for the effect of a higher serum ferritin (SF) level vs a lower SF level. A: death due to relapse/disease progression; B: death due to infection; C: death due to GVHD.

4. Discussion

This meta-analysis highlighted that a higher pre-transplantation SF level was associated with inferior OS and DFS, as well as an increased risk of NRM, relapse and SOS. However, no association was found between the SF levels and grades II-IV aGVHD, or cGVHD. In addition, a notable relationship was observed between an elevated pre-transplantation SF level and a higher risk of infections, particularly fungal infection. Furthermore, a higher pre-transplantation SF level was correlated with an increased risk of death due to relapse/disease progression and infection, but not due to GVHD.

4.1. Results in relation to other studies

Although several previous meta-analyses have reported that a higher SF is related to inferior OS and increased NRM [8–11,14], they lack a more comprehensive description of the relationship between the SF levels and other outcomes of HSCT, such as GVHD, SOS, and infection, which increase the risk of transplant-related mortality and long-term survival. Only one meta-analysis conducted by Yan et al. [11] analyzed the relationship between SF level and the multiple outcomes of allo-HSCT. However, they did not include many recently published papers and did not perform sensitivity analysis, subgroup analysis, or publication bias analysis for the association of a higher SF level with acute/chronic GVHD and infection. In our meta-analysis, the association between the SF level and OS, DFS,

NRM, relapse, SOS, aGVHD, and cGVHD were systematically analyzed, and subgroup analyses by study location, cut-off value, variable type, disease type, graft type and outcome time point were performed. Sensitivity analyses indicated that our results for OS, DFS, NRM, relapse, aGVHD, cGVHD, SOS, infection, and causes of death were robust to a degree.

Previous studies focused only on the impact of the SF level on outcomes of allo-HSCT. In our meta-analysis, studies involving alloand auto-HSCT were included in subgroup analysis. Subgroup analyses showed that an elevated pre-transplantation SF level was significantly associated with inferior OS and DFS, as well as higher risks of NRM and relapse in patients with allo- and auto-HSCT. These results highlight the importance of maintaining the SF level within a reasonable range before transplantation in both alloand auto-HSCT. Importantly, several studies have demonstrated significant reductions in the SF level and notable improvements in OS and DFS after treatment of iron chelation before or after HSCT [83–86]. Pan et al. [63] suggested that chelating excess iron to an SF level below 1000 ng/mL is necessary and could potentially improve outcomes. However, attempts to reduce pretreatment ferritin levels should not interfere with the timing of transplantation in high-risk acute leukemia patients eligible for allogeneic hematopoietic cell transplantation (HCT).

Graft-versus-host disease, which results from allo-responses triggered by donor T-cells against recipient histocompatibility antigens, poses a significant challenge in patients undergoing allo-HSCT. It is closely linked to adverse outcomes and diminished long-term quality of life [87]. To date, data regarding the role of the pre-transplantation SF level in the pathogenesis of GVHD are controversial and often inconsistent. A previous meta-analysis reported that higher a SF level was strongly related to a lower incidence of cGVHD (OR, 0.74; 95 % CI: 0.58–0.96; p < 0.05), but not aGVHD (OR, 1.08; 95 % CI: 0.72–1.62; p = 0.70) [11]. In contrast, our meta-analysis indicated that an elevated pre-transplantation SF level was not significantly related to grade II-IV aGVHD (RR, 1.09; 95 % CI, 0.96–1.24), or cGVHD (RR, 0.93; 95 % CI, 0.78–1.12). In addition, our meta-analysis showed that a higher pre-transplantation SF level was significantly associated with a higher risk of death due to relapse/disease progression and infection, which may contribute to worse survival in patients undergoing HSCT, but is not associated with a risk of death due to GVHD. These findings suggest that a higher pre-transplantation SF level is not associated with GVHD.

Hepatic sinusoidal obstruction syndrome, commonly known as veno-occlusive disease of the liver, is an early complication of HSCT. It should be noted that our study was the first meta-analysis to estimate the association between the SF level and the risk of SOS. The pooled RR indicate that the pre-transplantation SF level act as a significant risk factor for developing SOS. An elevated SF level indicates iron overload, which can catalyze the formation of hydroxyl radicals, leading to hepatic tissue injury. Chueh et al. demonstrated that iron-chelating therapy using deferasirox effectively reduced the pre-transplantation SF level and, subsequently decreased the incidence of hepatic SOS following allo-HSCT [88].

In addition to causing oxidative stress, iron also serves as a crucial cofactor in the growth of numerous microbial pathogens [89]. An elevated SF level can create an environment conductive to the proliferation of bacteria and fungi that rely heavily on freely available iron [90]. In addition, iron overload can adversely affect the phagocytosis of immune cells [91], which may damage the immune barrier and lead to infection. Therefore, it is intriguing to speculate on the impact of an elevated SF level in patients with infections who had HSCT. As expected, the pooled results showed that an elevated pre-transplantation SF level was associated with an increased risk of infection. Unexpectedly, an elevated SF level was not significantly related to bacterial infection, but was related to an increased risk of fungal infection. Owing to the use of antibiotics, antibacterial prophylaxis is strongly considered for recipients of HSCT, as infections can be effectively prevented [92]. In a cohort of 112 patients with hematological malignancies who had allo-HSCT without antibacterial prophylaxis, Kanda et al. [47] found that a higher pre-transplantation SF level was a significant risk factor for bacterial infection. However, other cohorts [75,79,81] of patients who received antibacterial prophylaxis, did not show a significant association between the SF level and bacterial infection. Although fluconazole prophylaxis has decreased the occurrence of fungal infections caused by susceptible microorganisms, it has led to a subsequent increase in resistant species [93]. Therefore, patients with a high pre-transplantation SF level need more attention regarding the risk of fungal infection.

Since the course of post-HSCT is quite long, any outcomes can occur immediately after HSCT or can occur even more than one year after HSCT. Long-term outcomes may have been influenced by various factors after HSCT. The occurrence of outcomes such as aGVHD, cGVHD and SOS is defined by specific diagnostic criteria: aGVHD occurs within 100 days after transplantation, cGVHD appears after 100 days, and SOS occurs within 30 days post-transplantation. While, the reported outcome measures (such as OS, DFS, NRM, Relapse) among the included studies span different time points, including 1-year, 2-year, 3-year, 4-year, 5-year and 6-year intervals. In our meta-analysis, we conducted subgroup analyses based on outcome time points, and results indicated that the associations between pre-transplantation SF level and the outcomes (including OS, DFS, NRM, Relapse) were still significant. Subgroup analyses based on variable type (univariate analysis or multivariate analysis) showed that the overall combined risk estimates were not significantly altered. Therefore, we suggested that the impact of pre-transplant SF levels on survival after transplantation is long-term and independent. However, regarding to the occurrence of infections post-transplantation, some of the studies included in our meta-analysis lack specific timing details. Thus, whether elevated pre-transplant SF level affects only early infections after HSCT or has a long-term impact on infections requires further extensive and detailed research to confirm.

4.2. Limitations of the review

In addition to the aforementioned strengths, our meta-analysis has several limitations. First, the cut-off SF level differed among the included studies. Although SF > 1000 ng/mL is commonly regarded as iron-overload, several studies have calculated the impact of the SF level using different thresholds. By subgroup analysis, it was show that SF > 1000 ng/mL was significantly associated with poorer OS and DFS and increased NRM; however, we cannot suggest that 1000 ng/mL is the optimal threshold for iron-overload, which may influence the outcomes of HSCT. Second, the follow-up duration varied considerably among the included studies, which could have

impacted the reliability of the pooled results. Third, the number of studies specific to each subtype of hematological malignancy remains insufficient as most studies have included patients with different types of hematological malignancies. Tachibana et al. [94] indicated that the pre-HSCT serum ferritin level is significantly associated with the outcome of acute myeloid leukemia, but not acute lymphocytic leukemia. These subtypes differ with regard to disease biology; thus, they should be analyzed separately. In this meta-analysis, the association between the SF level and HM and HNM was analyzed separately.

5. Conclusions

This study highlights that a higher pre-transplantation SF level is associated with inferior OS and DFS in both allogeneic and autologous HSCT patients. Our results suggest that there may be an increased risk of relapse and infection in patients with a higher pre-transplantation SF level, which contribute to worse OS. Unexpectedly, a higher SF level was related to a higher risk of fungal infection, but not bacterial infection, indicating that patients with a high pre-transplantation SF level require greater attention paid to the risk of fungal infection after HSCT. Overall, our meta-analysis serves as a valuable resource to inform clinical practice and guide the development of individualized preemptive or therapeutic strategies to enhance HSCT outcomes. Therefore, well-designed prospective studies are necessary to deepen our understanding of this relationship. Crucially, these studies should aim to determine whether early iron chelation therapy can enhance OS following HSCT.

Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SF, Serum ferritin; HSCT, Hematopoietic stem cell transplantation; OS, Overall survival; DFS, Disease-free survival; NRM, Non-relapse mortality; SOS, Sinusoidal obstruction syndrome; ROS, Reactive oxygen species; MRI, Magnetic resonance imaging, SQID, Superconducting quantum interference device; HM, Hematological malignancies; HNM, Hematological non-malignant disease; SAA, Severe aplastic anemia; HR, Hazard ratio; RR, Risk ratio; CI, Confidence intervals; allo-HSCT, allogeneic HSCT; auto-HSCT, autologous HSCT; UCBT, Umbilical cord blood transplantation; VOD, Veno-occlusive disease.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Data availability statement

Data associated with my study has not been deposited into a publicly available repository. All data generated or analyzed during this study are included in this article and its supplementary material files.

Funding

This work was funded by National Natural Science Foundation of China (NSFC 82100123, 82170141, 81870136) and Natural Science Foundation of Zhejiang Province (LXZ22H080001). The funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.

CRediT authorship contribution statement

Wenjue Pan: Writing – original draft, Resources, Investigation, Formal analysis, Data curation, Conceptualization. Qibei Teng: Writing – original draft, Resources, Investigation, Formal analysis, Data curation, Conceptualization. Huiqiao Chen: Resources, Investigation, Formal analysis. Liangning Hu: Resources, Investigation, Formal analysis. Xiaoyan Yue: Resources, Investigation, Formal analysis. Zijun Qian: Software, Methodology, Formal analysis. Ruoyu Dong: Software, Methodology, Conceptualization. Hongyu Zhou: Software, Methodology, Formal analysis. Xiujie Zhao: Software, Methodology, Formal analysis. Haowen Xiao: Writing – review & editing, Validation, Supervision, Project administration, Funding acquisition. Shufen Wang: Writing – review & editing, Writing – original draft, Visualization, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e37436.

References

- B.J. Crielaard, T. Lammers, S. Rivella, Targeting iron metabolism in drug discovery and delivery, Nat. Rev. Drug Discov. 16 (6) (2017) 400–423, https://doi.org/ 10.1038/nrd.2016.248.
- [2] S.J. Dixon, B.R. Stockwell, The role of iron and reactive oxygen species in cell death, Nat. Chem. Biol. 10 (1) (2014) 9–17, https://doi.org/10.1038/ nchembio.1416.
- [3] P. Tenneti, A. Chojecki, M.A. Knovich, Iron overload in the HCT patient: a review, Bone Marrow Transplant. 56 (8) (2021) 1794–1804, https://doi.org/ 10.1038/s41409-021-01244-7.
- [4] N. Jacobi, L. Herich, Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation, Eur. J. Haematol. 97 (4) (2016) 336–341, https://doi.org/10.1111/ejh.12734.
- [5] S. Mavrogeni, E.D. Gotsis, E. Berdousi, V. Ladis, D. Verganelakis, P. Toulas, D.V. Cokkinos, Myocardial and hepatic T2* magnetic resonance evaluation in exthalassemic patients after bone-marrow transplantation, Int. J. Cardiovasc. Imag. 23 (6) (2007) 739–745, https://doi.org/10.1007/s10554-006-9203-7.
- [6] E. Atilla, S.K. Toprak, T. Demirer, Current review of iron overload and related complications in hematopoietic stem cell transplantation, Turk. J. Haematol. 34 (1) (2017) 1–9, https://doi.org/10.4274/tjh.2016.0450.
- [7] L.I. Gordon, S.G. Brown, M.S. Tallman, A.W. Rademaker, S.A. Weitzman, H.M. Lazarus, C.H. Kelley, C. Mangan, H. Rubin, R.M. Fox, et al., Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity, Free radical biology & medicine 18 (3) (1995) 383–389, https://doi.org/10.1016/0891-5849(94)e0145-9.
- [8] P. Armand, H.T. Kim, J.M. Virtanen, R.K. Parkkola, M.A. Itälä-Remes, N.S. Majhail, L.J. Burns, T. DeFor, B. Trottier, U. Platzbecker, J.H. Antin, M. Wermke, Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis, Biol. Blood Marrow Transplant. 20 (8) (2014) 1248–1251, https://doi.org/ 10.1016/j.bbmt.2014.04.024.
- [9] W. Guo, A. Dong, M. He, X. Lin, R. Yao, B. Zhu, X. Pan, J. Jie, A meta-analysis for effects of elevated pre-transplantation serum ferritin on the outcomes in patients undergoing hematopoietic stem cell transplantation, Cancer Invest. 34 (7) (2016) 340–347, https://doi.org/10.1080/07357907.2016.1197236.
- [10] C. Pileggi, M.D. Sanzo, V. Mascaro, M.G. Marafioti, F.S. Costanzo, M. Pavia, Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: results of a meta-analysis of observational studies, PLoS One 12 (6) (2017), https://doi.org/10.1371/journal.pone.0179016.
- [11] Z. Yan, X. Chen, H. Wang, Y. Chen, L. Chen, P. Wu, W. Wang, Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, Medicine (United States) 97 (27) (2018), https://doi.org/10.1097/MD.00000000010310.
- [12] N.S. Young, Aplastic anemia, N. Engl. J. Med. 379 (17) (2018) 1643–1656, https://doi.org/10.1056/NEJMra1413485.
- [13] S.B. Killick, N. Bown, J. Cavenagh, I. Dokal, T. Foukaneli, A. Hill, P. Hillmen, R. Ireland, A. Kulasekararaj, G. Mufti, J.A. Snowden, S. Samarasinghe, A. Wood, J. C. Marsh, H. British Society for Standards in, Guidelines for the diagnosis and management of adult aplastic anaemia, Br. J. Haematol. 172 (2) (2016) 187–207, https://doi.org/10.1111/bjh.13853.
- [14] Z. Wang, M. Jia, H. Zhao, Y. Cheng, Z. Luo, Y. Chen, X. Xu, Y. Tang, Prognostic impact of pretransplantation hyperferritinemia in adults undergoing allogeneic hematopoietic SCT: a meta-analysis, Bone Marrow Transplant. 49 (10) (2014) 1339–1340, https://doi.org/10.1038/bmt.2014.127.
- [15] Z. Yan, X. Chen, H. Wang, Y. Chen, L. Chen, P. Wu, W. Wang, Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis, Medicine (Baltim.) 97 (27) (2018) e10310, https://doi.org/10.1097/md.00000000010310.
- [16] M. Morado, E. Ojeda, J. Garcia-Bustos, M.J. Aguado, R. Arrieta, E. Quevedo, A. Navas, F. Hernandez-Navarro, Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study, Hematology 4 (6) (1999) 505–512, https://doi.org/10.1080/10245332.1999.11746478.
- [17] S.H. Lee, K.H. Yoo, K.W. Sung, H.H. Koo, Y.J. Kwon, M.M. Kwon, H.J. Park, B.K. Park, Y.Y. Kim, J.A. Park, H.J. Im, J.J. Seo, H.J. Kang, H.Y. Shin, H.S. Ahn, Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome, Bone Marrow Transplant. 45 (8) (2010) 1287–1293, https://doi.org/10.1038/bmt.2009.349.
- [18] S.S. Dadwal, B. Tegtmeier, X. Liu, P. Frankel, J. Ito, S.J. Forman, V. Pullarkat, Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation, Eur. J. Haematol. 94 (3) (2015) 235–242, https://doi.org/10.1111/ejh.12421.
- [19] A. Altes, A.F. Remacha, P. Sarda, M. Baiget, A. Sureda, R. Martino, J. Briones, S. Brunet, C. Canals, J. Sierra, Early clinical impact of iron overload in stem cell transplantation. A prospective study, Ann. Hematol. 86 (6) (2007) 443–447, https://doi.org/10.1007/s00277-007-0266-x.
- [20] V. Pullarkat, S. Blanchard, B. Tegtmeier, A. Dagis, K. Patane, J. Ito, S.J. Forman, Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation, Bone Marrow Transplant. 42 (12) (2008) 799–805, https://doi.org/10.1038/bmt.2008.262.
- [21] M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ 372 (2021) n71, https://doi.org/10.1136/bmj. n71.
- [22] J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, M.R. Sydes, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials 8 (2007) 16, https://doi.org/10.1186/1745-6215-8-16.
- [23] D. Jackson, I.R. White, S.G. Thompson, Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses, Stat. Med. 29 (12) (2010) 1282–1297, https://doi.org/10.1002/sim.3602.
- [24] J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, L. Rushton, Comparison of two methods to detect publication bias in meta-analysis, JAMA 295 (6) (2006) 676–680, https://doi.org/10.1001/jama.295.6.676.
- [25] M.D. Jennions, A.P. Moller, Publication bias in ecology and evolution: an empirical assessment using the 'trim and fill' method, Biol Rev Camb Philos Soc 77 (2) (2002) 211–222, https://doi.org/10.1017/s1464793101005875.
- [26] S.Z. Aki, E. Suyani, Y. Bildaci, M.K. Cakar, N.A. Baysal, G.T. Sucak, Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation, Clin. Transplant. 26 (5) (2012) E513–E521, https://doi.org/10.1111/ctr.12028.
- [27] Malki MM. Al, J.Y. Song, D. Yang, T. Cao, I. Aldoss, S. Mokhtari, S. Dadwal, G. Marcucci, C. Karanes, D. Snyder, A. Nademanee, S.J. Forman, R. Nakamura, V. Pullarkat, Iron overload is associated with delayed engraftment and increased nonrelapse mortality in recipients of umbilical cord blood hematopoietic cell transplantation, Biol. Blood Marrow Transplant. 26 (9) (2020) 1697–1703, https://doi.org/10.1016/j.bbmt.2020.06.002.
- [28] E.P. Alessandrino, M.G. Della Porta, A. Bacigalupo, L. Malcovati, E. Angelucci, M.T. Van Lint, M. Falda, F. Onida, M. Bernardi, S. Guidi, B. Lucarelli, A. Rambaldi, R. Cerretti, P. Marenco, P. Pioltelli, C. Pascutto, R. Oneto, L. Pirolini, R. Fanin, A. Bosi, Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study, Haematologica 95 (3) (2010) 476–484, https://doi.org/10.3324/haematol.2009.011429.
- [29] L.C. Alva, U. Bacher, K. Seipel, B. Mansouri Taleghani, B.U. Mueller, U. Novak, T. Pabst, Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia, Transfusion 58 (10) (2018) 2365–2373, https://doi.org/10.1111/trf.14895.
- [30] P. Armand, H.T. Kim, C.S. Cutler, V.T. Ho, J. Koreth, J. Ritz, E.P. Alyea, J.H. Antin, R.J. Soiffer, A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation, Biol. Blood Marrow Transplant. 14 (1) (2008) 28–35, https://doi.org/10.1016/j. bbmt.2007.07.016.

- [31] C. Arndt, J.F. Beck, B. Gruhn, A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation, Eur. J. Haematol. 93 (6) (2014) 509–515, https://doi.org/10.1111/ejh.12390.
- [32] A.S. Artz, B. Logan, X. Zhu, G. Akpek, R.M. Bufarull, V. Gupta, H.M. Lazarus, M. Litzow, A. Loren, N.S. Majhail, R.H.T. Maziarz, P. McCarthy, U. Popat, W. Saber, S. Spellman, O. Ringden, A. Wickrema, M.C. Pasquini, K.R. Cookel, The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes, Haematol.go16.145847.
- [33] P. Barba, D. Valcarcel, J. Antonio Perez-Simon, F. Fernandez-Aviles, J. Luis Pinana, R. Martino, L. Lopez-Anglada, M. Rovira, I. Garcia-Cadenas, S. Novelli, E. Carreras, L. Lopez Corral, J. Sierra, Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies, Biol. Blood Marrow Transplant. 19 (4) (2013) 597–601, https://doi.org/10.1016/j.bbmt.2012.12.018.
- [34] A. Boehm, W.R. Sperr, P. Kalhs, H. Greinix, P. Valent, N. Worel, A. Kainz, M. Mitterbauer, M. Bojic, W. Rabitsch, Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience, Wien Klin. Wochenschr. 126 (1–2) (2014) 23–29, https://doi.org/10.1007/s00508-013-0449-5.
- [35] L. Chee, M. Tacey, B. Lim, A. Lim, J. Szer, D. Ritchie, Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation, Bone Marrow Transplant. 52 (6) (2017) 870–877, https://doi.org/10.1038/bmt.2017.51.
- [36] B.-S. Cho, Y.-W. Jeon, A.R. Hahn, T.-H. Lee, S.-S. Park, J.-H. Yoon, S.-E. Lee, K.-S. Eom, Y.-J. Kim, S. Lee, C.-K. Min, S.-G. Cho, J.-W. Lee, W.-S. Min, H.-J. Kim, Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia, Cancer Med. 8 (2) (2019) 501–514, https://doi.org/10.1002/cam4.1928.
- [37] E.M.P. Cremers, T. de Witte, L. de Wreede, D.-J. Eikema, L. Koster, A. van Biezen, J. Finke, G. Socie, D. Beelen, J. Maertens, A. Nagler, G. Kobbe, D. Ziagkos, M. Itala-Remes, T. Gedde-Dahl, J. Sierra, D. Niederwieser, P. Ljungman, Y. Beguin, Z.N. Ozkurt, A. Anagnostopoulos, P. Jindra, M. Robin, N. Kroeger, A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation, Leuk. Lymphoma 60 (10) (2019) 2404–2414, https://doi.org/10.1080/10428194.2019.1594215.
- [38] E.M.P. Cremers, A. van Biezen, L.C. de Wreede, M. Scholten, A. Vitek, J. Finke, U. Platzbecker, D. Beelen, R. Schwerdtfeger, L. Volin, N. Harhalakis, N. Blijlevens, A. Nagler, N. Kröger, T. de Witte, Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT, Ann. Hematol. 95 (12) (2016) 1971–1978, https://doi.org/10.1007/s00277-016-2802-z.
- [39] S.S. Dadwal, B. Tegtmeier, X. Liu, P. Frankel, J. Ito, S.J. Forman, V. Pullarkat, Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation, Eur. J. Haematol. 94 (3) (2015) 235–242, https://doi.org/10.1111/ejh.12421.
- [40] Y.A. Efebera, R.S. Thandi, R.M. Saliba, U. Popat, M. De Lima, A. Alousi, C. Hosing, G. Rondon, R. Champlin, S. Giralt, The impact of pre-stem cell transplant ferritin level on late transplant complications: an analysis to determine the potential role of iron overload on late transplant outcomes, Internet J. Hematol. 7 (1) (2009).
- [41] W. Fingrut, A. Law, W. Lam, F.V. Michelis, A. Viswabandya, J.H. Lipton, R. Kumar, J. Mattsson, D.D.H. Kim, Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level, Ann. Hematol. 100 (3) (2021) 789–798, https://doi.org/10.1007/ s00277-020-04363-1.
- [42] T. Goto, K. Ikuta, Y. Inamoto, S. Kamoshita, E. Yokohata, D. Koyama, K. Onodera, A. Seto, K. Watanabe, N. Imahashi, S. Tsukamoto, Y. Ozawa, K. Sasaki, M. Ito, Y. Kohgo, K. Miyamura, Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: quantification of iron burden by determining nontransferrin-bound iron, Int. J. Hematol. 97 (1) (2013) 125–134, https://doi.org/10.1007/s12185-012-1252-1.
- [43] A. Hilken, C. Langebrake, C. Wolschke, J.F. Kersten, H. Rohde, P. Nielsen, N. Kroeger, Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT), Ann. Hematol. 96 (8) (2017) 1379–1388, https://doi.org/10.1007/s00277-017-3034-6.
- [44] D.Y. Hwang, S.J. Kim, J.W. Cheong, Y. Kim, J.E. Jang, J.Y. Lee, Y.H. Min, W.I. Yang, J.S. Kim, High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma, Leuk. Lymphoma 57 (1) (2016) 51–57, https://doi.org/10.3109/10428194.2015.1041387.
- [45] N. Jacobi, L. Herich, Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation, Eur. J. Haematol. 97 (4) (2016) 336–341, https://doi.org/10.1111/ejh.12734.
- [46] J.E. Jang, S.J. Kim, J.-W. Cheong, S.Y. Hyun, Y.D. Kim, Y.R. Kim, J.S. Kim, Y.H. Min, Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia, Ann. Hematol. 94 (2) (2015) 275–282, https://doi.org/10.1007/s00277-014-2190-1.
- [47] J. Kanda, C. Mizumoto, T. Ichinohe, H. Kawabata, T. Saito, K. Yamashita, T. Kondo, S. Takakura, S. Ichiyama, T. Uchiyama, T. Ishikawa, Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation, Bone Marrow Transplant. 46 (2) (2011) 208–216, https://doi.org/10.1038/bmt.2010.108.
- [48] K. Kataoka, Y. Nannya, A. Hangaishi, Y. Imai, S. Chiba, T. Takahashi, M. Kurokawa, Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation, Biol. Blood Marrow Transplant. 15 (2) (2009) 195–204, https://doi. org/10.1016/j.bbmt.2008.11.012.
- [49] Y.R. Kim, J.S. Kim, J.-W. Cheong, J.W. Song, Y.H. Min, Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies, Acta Haematol. 120 (3) (2008) 182–189, https://doi.org/10.1159/ 000187646.
- [50] J. Kloehn, G. Brodt, J. Ernst, B. Gruhn, Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients, J. Cancer Res. Clin. Oncol. 148 (6) (2022) 1447–1455, https://doi.org/10.1007/s00432-021-03732-1.
- [51] T. Konuma, S. Kato, M. Oiwa-Monna, A. Tojo, S. Takahashi, Pretransplant hyperferritinemia has no effect on the outcome of myeloablative cord blood transplantation for acute leukemia and myelodysplastic syndrome, Ann. Hematol. 93 (6) (2014) 1071–1072, https://doi.org/10.1007/s00277-013-1932-9.
- [52] F.T. Küpesiz, V. Hazar, N. Eker, E. Guler, M.A. Yesilipek, G. Tuysuz, A. Kupesiz, Retrospective evaluation of relationship between iron overload and transplantation complications in pediatric patient who underwent allogeneic stem cell transplantation due to acute leukemia and myelodysplastic syndrome, J. Pediatr. Hematol. Oncol. 42 (5) (2020) e315–e320, https://doi.org/10.1097/MPH.00000000001829.
- [53] Z.Y. Lim, V. Fiaccadori, S. Gandhi, J. Hayden, M. Kenyon, R. Ireland, J. Marsh, A.Y.L. Ho, G.J. Mufti, A. Pagliuca, Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation, Leuk. Res. 34 (6) (2010) 723–727, https://doi.org/10.1016/j.leukres.2009.10.028.
- [54] F. Lin, Y. Zuo, Y. Zhang, Y. Cheng, T. Han, X. Mo, P. Suo, Y. Sun, F. Tang, F. Wang, C. Yan, Y. Chen, W. Han, J. Wang, Y. Wang, X. Zhang, K. Liu, X. Huang, L. Xu, The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents, Pediatr. Blood Cancer 69 (9) (2022), https://doi.org/10.1002/pbc.29845.
- [55] A. Mahindra, B. Bolwell, R. Sobecks, L. Rybicki, B. Pohlman, R. Dean, S. Andresen, J. Sweetenham, M. Kalaycio, E. Copelan, Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma, Biol. Blood Marrow Transplant. 14 (11) (2008) 1239–1244, https://doi.org/ 10.1016/j.bbmt.2008.08.009.
- [56] A. Mahindra, B. Bolwell, R. Sobecks, L. Rybicki, B. Pohlman, R. Dean, S. Andresen, J. Sweetenham, M. Kalaycio, E. Copelan, Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation, Br. J. Haematol. 146 (3) (2009) 310–316, https://doi.org/10.1111/j.1365-2141.2009.07774.x.
- [57] S.C. Maradei, A. Maiolino, A.M. De Azevedo, M. Colares, L.F. Bouzas, M. Nucci, Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation, Blood 114 (6) (2009) 1270–1275, https://doi.org/10.1182/blood-2009-03-212282.
- [58] K. Matsumoto, W. Yamamoto, E. Ogusa, E. Sugimoto, A. Maruta, Y. Ishigatsubo, H. Kanamori, Impact of pretransplant serum ferritin on outcome in adult patients receiving cord blood transplant for acute leukemia, Leuk. Lymphoma 55 (2) (2014) 460–461, https://doi.org/10.3109/10428194.2013.804918.

- [59] N. Maximova, G. Ferrara, M. Minute, A. Pizzol, V. Kiren, M. Montico, M. Gregori, P. Tamaro, Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant, Int. J. Hematol. 99 (6) (2014) 766–772, https://doi.org/10.1007/s12185-014-1578-y.
- [60] A. Ohmoto, S. Fuji, A. Miyagi-Maeshima, S.W. Kim, K. Tajima, T. Tanaka, K. Okinaka, S. Kurosawa, Y. Inamoto, H. Taniguchi, T. Fukuda, Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection, Bone Marrow Transplant. 52 (8) (2017) 1201–1203, https://doi.org/10.1038/bmt.2017.93.
- [61] B. Oran, P. Kongtim, U. Popat, M. de Lima, E. Jabbour, X. Lu, J. Chen, G. Rondon, P. Kebriaei, S. Ahmed, B. Andersson, A. Alousi, S. Ciurea, E. Shpall, R. E. Champlin, Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation, Biol. Blood Marrow Transplant. 20 (10) (2014) 1618–1625, https://doi.org/10.1016/j.bbmt.2014.06.022.
- [62] E. Ozyilmaz, M. Aydogdu, G. Sucak, S.Z. Aki, Z.N. Ozkurt, Z.A. Yegin, N. Kokturk, Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload, Bone Marrow Transplant. 45 (10) (2010) 1528–1533, https://doi.org/10.1038/bmt.2009.383.
- [63] T. Pan, Y. Ji, H. Liu, B. Tang, K. Song, X. Wan, W. Yao, G. Sun, J. Wang, Z. Sun, Impact of Iron overload and Iron Chelation with deferasirox on outcomes of patients with severe aplastic anemia after allogeneic hematopoietic stem cell transplantation, Transplantation and cellular therapy (2023), https://doi.org/ 10.1016/j.jtct.2023.04.016.
- [64] O. Penack, C. Peczynski, S. van der Werf, J. Finke, A. Ganser, H. Schoemans, J. Pavlu, R. Niittyvuopio, W. Schroyens, L. Kaynar, I.W. Blau, W.J.F.M. van der Velden, J. Sierra, A. Cortelezzi, G. Wulf, P. Turlure, M. Rovira, Z. Ozkurt, M.J. Pascual-Cascon, M.C. Moreira, J. Clausen, H. Greinix, R.F. Duarte, G.W. Basak, Association of serum ferritin levels before start of conditioning with mortality after alloSCT - a prospective, non-interventional study of the ebmt transplant complications working party. Front. Immunol. 11 (2020), https://doi.org/10.3389/fimmu.2020.00586.
- [65] S. Prem, E.G. Atenafu, W. Lam, A. Law, F.V. Michelis, D. Kim, A. Viswabandya, J. Howard Lipton, J. Mattsson, R. Kumar, Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival, Eur. J. Haematol. 104 (2) (2020) 116–124, https://doi.org/10.1111/ejh.13353.
- [66] V. Pullarkat, S. Blanchard, B. Tegtmeier, A. Dagis, K. Patane, J. Ito, S.J. Forman, Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation, Bone Marrow Transplant. 42 (12) (2008) 799–805, https://doi.org/10.1038/bmt.2008.262.
- [67] S. Sakamoto, H. Kawabata, J. Kanda, T. Uchiyama, C. Mizumoto, T. Kondo, K. Yamashita, T. Ichinohe, T. Ishikawa, N. Kadowaki, A. Takaori-Kondo, Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, Int. J. Hematol. 97 (1) (2013) 109–116, https://doi.org/10.1007/s12185-012-1229-0.
- [68] S. Sivgin, S. Baldane, L. Kaynar, F. Kurnaz, C. Pala, H. Sivgin, A. Ozturk, M. Cetin, A. Unal, B. Eser, Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation, Neoplasma 59 (2) (2012) 183–190, https://doi.org/10.4149/ neo_2012_024.
- [69] S. Sivgin, M.F. Karamustafaoglu, E. Yildizhan, G. Zararsiz, L. Kaynar, B. Eser, M. Cetin, A. Unal, The prognostic significance of elevated serum ferritin levels prior to transplantation in patients with lymphoma who underwent autologous hematopoietic stem cell transplantation (autoHSCT): role of iron overload, Clin. Lymphoma, Myeloma & Leukemia 16 (2016) S152–S158, https://doi.org/10.1016/j.clml.2016.02.006.
- [70] K. Strasser-Weippl, H. Ludwig, Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation, Leuk. Lymphoma 55 (11) (2014) 2520–2524, https://doi.org/10.3109/10428194.2014.891025.
- [71] G.T. Sucak, Z.A. Yegin, Z.N. Ozkurt, S.Z. Aki, M. Yagci, Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation, Transplant. Proc. 42 (5) (2010) 1841–1848, https://doi.org/10.1016/j.transproceed.2009.11.049.
- [72] T. Tachibana, M. Tanaka, A. Numata, H. Takasaki, S. Ito, R. Ohshima, M. Hagihara, E. Yamazaki, N. Tomita, K. Fujimaki, J. Taguchi, R. Sakai, H. Fujita, S. Fujisawa, A. Maruta, Y. Ishigatsubo, H. Kanamori, Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk, Leuk. Lymphoma 53 (3) (2012) 456–461, https://doi.org/10.3109/10428194.2011.619607.
- [73] T. Tachibana, M. Tanaka, H. Takasaki, A. Numata, S. Ito, R. Watanabe, R. Hyo, R. Ohshima, M. Hagihara, R. Sakai, S. Fujisawa, N. Tomita, H. Fujita, A. Maruta, Y. Ishigatsubo, H. Kanamori, Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies, Int. J. Hematol. 93 (3) (2011) 368–374, https://doi.org/10.1007/s12185-011-0784-0.
- [74] H. Takasaki, M. Tanaka, T. Tachibana, A. Numata, K. Fujimaki, R. Sakai, S. Fujisawa, N. Tomita, H. Fujita, A. Maruta, Y. Ishigatsubo, H. Kanamori, Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy, Int. J. Hematol. 95 (3) (2012) 291–298, https://doi.org/10.1007/s12185-012-1009-x.
- [75] M. Tanaka, H. Kanamori, K. Matsumoto, T. Tachibana, A. Numata, K. Ohashi, T. Kobayashi, C. Nakaseko, Y. Kanda, E. Yamazaki, S. Fujisawa, J. Ooi, T. Sakura, N. Aotsuka, M. Onoda, S. Machida, J. Kato, K. Usuki, R. Watanabe, J. Taguchi, S. Yano, T. Saito, S. Takahashi, H. Sakamaki, S. Okamoto, T. Kanto Study Grp Cell, Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy, Bone Marrow Transplant. 50 (5) (2015) 727–733, https://doi.org/10.1038/bmt.2015.17.
- [76] S.C. Thambiah, E. George, I.N. Samsudin, L.H. Hong, L.L. Chuo, N. Ramli, M.Z. Zakaria, Pre-transplantation serum ferritin as a prognostic marker in allogeneic haemopoietic stem cell transplant patients in a tertiary care hospital in Malaysia, NMJI (Natl. Med. J. India) 29 (3) (2016) 136–140.
- [77] J.E. Vaughn, B.E. Storer, P. Armand, R. Raimondi, C. Gibson, A. Rambaldi, F. Ciceri, R. Oneto, B. Bruno, P.J. Martin, B.M. Sandmaier, R. Storb, M.L. Sorror, Design and validation of an augmented hematopoietic cell transplantation-comorbidity index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation, Biol. Blood Marrow Transplant. 21 (8) (2015) 1418–1424, https://doi.org/10.1016/j. bbmt.2015.04.002.
- [78] A. Wahlin, F. Lorenz, M. Fredriksson, M. Remberger, B.E. Wahlin, H. Hagglund, Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts, Med. Oncol. 28 (2) (2011) 552–558, https://doi.org/10.1007/s12032-010-9496-1.
- [79] M. Wermke, A. Schmidt, J.M. Middeke, K. Sockel, M. von Bonin, C. Schoenefeldt, S. Mair, V. Plodeck, M. Laniado, G. Weiss, J. Schetelig, G. Ehninger, I. Theurl, M. Bornhaeuser, U. Platzbecker, MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation, Clin. Cancer Res. 18 (23) (2012) 6460–6468, https://doi.org/10.1158/1078-0432.Ccr-12-1683.
- [80] J.-H. Yoon, G.J. Min, S.-S. Park, S. Park, S.-E. Lee, B.-S. Cho, Y.-J. Kim, S. Lee, H.-J. Kim, C.-K. Min, S.-G. Cho, J.W. Lee, K.-S. Eom, HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis, Therapeutic Advances in Hematology 11 (2020), https://doi.org/10.1177/2040620720936935.
- [81] X. Zhang, Y. Shi, Y. Huang, G. Zhang, Y. He, E. Jiang, J. Wei, D. Yang, Q. Ma, R. Zhang, W. Zhai, S. Feng, M. Han, Serum ferritin is a different predictor from transfusion history for allogeneic transplantation outcome in patients with severe aplastic anemia, Hematology 23 (5) (2018) 291–298, https://doi.org/ 10.1080/10245332.2017.1390929.
- [82] A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur. J. Epidemiol. 25 (9) (2010) 603–605, https://doi.org/10.1007/s10654-010-9491-z.
- [83] S. Sivgin, S. Baldane, G. Akyol, M. Keklik, L. Kaynar, F. Kurnaz, C. Pala, G. Zararsiz, M. Cetin, B. Eser, A. Unal, The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload, Transfus. Apher. Sci. 49 (2) (2013) 295–301, https:// doi.org/10.1016/j.transci.2013.07.004.
- [84] J.W. Lee, H.J. Kang, E.K. Kim, H. Kim, H.Y. Shin, H.S. Ahn, Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children, Bone Marrow Transplant. 44 (12) (2009) 793–797, https://doi.org/10.1038/bmt.2009.88.
- [85] S. Essmann, M. Heestermans, A. Dadkhah, D. Janson, C. Wolschke, F. Ayuk, N.M. Kröger, C. Langebrake, Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation, Transplantation and Cellular Therapy 29 (1) (2023) 42.e41–42.e46, https://doi.org/10.1016/j.jtct.2022.10.002.
- [86] T. Tachibana, J. Kanda, S. Machida, T. Saito, M. Tanaka, Y. Najima, S. Koyama, T. Miyazaki, E. Yamamoto, M. Takeuchi, S. Morita, Y. Kanda, H. Kanamori, S. Okamoto, Ksgct, Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302), Int. J. Hematol. 107 (5) (2018) 578–585, https://doi.org/10.1007/s12185-017-2396-9.

- [87] L.P. Xu, Z.L. Xu, S.Q. Wang, D.P. Wu, S.J. Gao, J.M. Yang, L.H. Xia, Q.F. Liu, M. Jiang, H. Bai, X. Zhang, X. Wang, X.J. Huang, Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study, Sci. Bull. 67 (9) (2022) 963–970, https://doi.org/ 10.1016/j.scib.2022.01.024.
- [88] H.W. Chueh, K.W. Sung, S.H. Lee, K.H. Yoo, H.H. Koo, J.Y. Kim, E.J. Cho, Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors, Pediatr. Blood Cancer 58 (3) (2012) 441–447, https://doi.org/10.1002/pbc.23198.
- [89] U.E. Schaible, S.H. Kaufmann, Iron and microbial infection, Nat. Rev. Microbiol. 2 (12) (2004) 946–953, https://doi.org/10.1038/nrmicro1046.
- [90] J.J. Marx, Iron and infection: competition between host and microbes for a precious element, Best Pract. Res. Clin. Haematol. 15 (2) (2002) 411-426.
- [91] E.M. Walker Jr., S.M. Walker, Effects of iron overload on the immune system, Ann. Clin. Lab. Sci. 30 (4) (2000) 354-365.
- [92] S. Trifilio, A. Verma, J. Mehta, Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice, Bone Marrow Transplant. 33 (7) (2004) 735–739, https://doi.org/10.1038/sj.bmt.1704423.
- [93] C. Cattaneo, G. Quaresmini, S. Casari, M.A. Capucci, M. Micheletti, E. Borlenghi, L. Signorini, A. Re, G. Carosi, G. Rossi, Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution, J. Antimicrob. Chemother. 61 (3) (2008) 721–728, https://doi.org/10.1093/jac/dkm514.
- [94] T. Tachibana, M. Tanaka, H. Takasaki, A. Numata, A. Maruta, Y. Ishigatsubo, H. Kanamori, Pre-SCT serum ferritin is a prognostic factor in adult AML, but not ALL, Bone Marrow Transplant. 46 (9) (2011) 1268–1269, https://doi.org/10.1038/bmt.2010.271.